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Abstract
Cytosolic detection of pathogen associated molecular patterns is a key event in host discrimination between
commensal and pathogenic microbes. While cytosolic access is critical for the pathogenesis of intracellular
bacteria, access to the cytosolic compartment by extracellular bacteria is less well understood. The leading
extracellular pathogen Streptococcus pneumoniae (the pneumococcus) activates intracellular innate immune
responses, but unlike intracellular bacterial pathogens, S. pneumoniae is killed and degraded upon uptake by
phagocytic cells. The pneumococcus serially colonizes the human upper respiratory tract and is eventually
cleared over a period of weeks by the host immune response. Previous studies have defined a critical role for
the cytosolic pattern recognition receptor Nod2 in driving the macrophage recruitment that leads to clearance
of pneumococci, although the mechanism by which pneumococcal cell wall components access the cytosol to
activate Nod2 signaling remains unclear.
In these studies, we demonstrate that cytosolic access of pneumococcal components is dependent on bacterial
degradation by the host muramidase lysozyme and on the activity of the bacterial pore-forming toxin
pneumolysin. We propose a model in which S. pneumoniae is phagocytosed by macrophages whereupon it is
killed and degraded by lysozyme, allowing bacterial cell wall components to escape into the host cell cytosol
via the action of pneumolysin on the phagosome membrane. We further define a host mechanism that limits
the amount of pneumococcal products that transit to the cytosol, although this defense is insufficient and the
macrophage undergoes pro-inflammatory cell death.
This cell death is triggered by the formation of inflammasomes, multi-protein cytosolic complexes, that
activate caspase-1 to drive secretion of the pro-inflammatory cytokine interleukin-1 beta (IL-1β). We show
that sensing by the type 1 IL-1 receptor (Il1r1-/-) is required for the host to effectively recruit macrophages to
the nasopharynx and that Il1r1-/- mice have delayed bacterial clearance. Furthermore, sensing of IL-1
cytokines contributes to inflammation in the nasopharynx, which may promote S. pneumoniae growth or
transmission, but does not impact the adaptive immune response of the host. This suggests that a bacterial
toxin and the subsequent intracellular innate immune sensing it causes may help the pneumococcus promote
its extracellular lifestyle.
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ABSTRACT 
 
THE ROLE OF CYTOSOLIC ACCESS IN STREPTOCOCCUS 
PNEUMONIAE NASOPHARYNGEAL COLONIZATION 
 
Jamie K. Lemon 
Jeffrey N. Weiser 
 
Cytosolic detection of pathogen associated molecular patterns is a key 
event in host discrimination between commensal and pathogenic microbes. 
While cytosolic access is critical for the pathogenesis of intracellular bacteria, 
access to the cytosolic compartment by extracellular bacteria is less well 
understood. The leading extracellular pathogen Streptococcus pneumoniae 
(the pneumococcus) activates intracellular innate immune responses, but 
unlike intracellular bacterial pathogens, S. pneumoniae is killed and degraded 
upon uptake by phagocytic cells. The pneumococcus serially colonizes the 
human upper respiratory tract and is eventually cleared over a period of 
weeks by the host immune response. Previous studies have defined a critical 
role for the cytosolic pattern recognition receptor Nod2 in driving the 
macrophage recruitment that leads to clearance of pneumococci, although 
the mechanism by which pneumococcal cell wall components access the 
cytosol to activate Nod2 signaling remains unclear. 
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In these studies, we demonstrate that cytosolic access of 
pneumococcal components is dependent on bacterial degradation by the host 
muramidase lysozyme and on the activity of the bacterial pore-forming toxin 
pneumolysin. We propose a model in which S. pneumoniae is phagocytosed 
by macrophages whereupon it is killed and degraded by lysozyme, allowing 
bacterial cell wall components to escape into the host cell cytosol via the 
action of pneumolysin on the phagosome membrane. We further define a 
host mechanism that limits the amount of pneumococcal products that transit 
to the cytosol, although this defense is insufficient and the macrophage 
undergoes pro-inflammatory cell death. 
This cell death is triggered by the formation of inflammasomes, multi-
protein cytosolic complexes, that activate caspase-1 to drive secretion of the 
pro-inflammatory cytokine interleukin-1 beta (IL-1β). We show that sensing 
by the type 1 IL-1 receptor (Il1r1-/-) is required for the host to effectively 
recruit macrophages to the nasopharynx and that Il1r1-/- mice have delayed 
bacterial clearance. Furthermore, sensing of IL-1 cytokines contributes to 
inflammation in the nasopharynx, which may promote S. pneumoniae growth 
or transmission, but does not impact the adaptive immune response of the 
host. This suggests that a bacterial toxin and the subsequent intracellular 
innate immune sensing it causes may help the pneumococcus promote its 
extracellular lifestyle. !
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CHAPTER I 
 
 
Introduction 
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Historical Background 
 Streptococcus pneumoniae (the pneumococcus) was independently 
isolated in 1880 by both George Sternberg in the United States (252) and 
Louis Pasteur in France (209). Historically, Pasteur receives credit for the 
discovery because he published three months before Sternberg, although 
Pasteur’s experiments were actually performed later (11). Both men injected 
human saliva subcutaneously into rabbits – for Pasteur the saliva was from a 
child and for Sternberg the sample was his own saliva – and thereafter 
recovered a lancet-shaped diplococcal bacterium from the blood of the 
inoculated rabbits. This organism was first referred to as Pneumococcus in 
1886 (82) for its association with pneumonia, and in 1920 it was renamed 
Diplococcus pneumoniae to reflect both its cellular morphology and clinical 
presentation (281). In 1974 it received its current designation of 
Streptococcus pneumoniae (64) because it grows in short chains in broth 
culture, a defining characteristic of the Streptococcus genus. While initially 
isolated from a state of carriage, within a decade of the pneumococcus’ 
discovery it had been recovered from cases of pneumonia (96, 153), 
septicemia (258), meningitis (198), otitis media (289), and even arthritis 
(274).  
 Although often studied for the variety of human diseases it can cause, 
perhaps the most important contribution the pneumococcus has made to our 
understanding of biology has little to do with its clinical manifestations in 
humans. In 1928 Fred Griffith published the now famous ‘Griffith’s 
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experiment’ that demonstrated the principle of bacterial transformation (95). 
Griffith observed that injecting mice with an unencapsulated pneumococcal 
strain caused no disease, while the mice rapidly succumbed to infection 
following injection of an encapsulated strain. In his experiment, Griffith 
injected mice with a mixture of live unencapsulated and heat-killed 
encapsulated pneumococci. The mice quickly died and only live encapsulated 
organisms could be recovered. As an added layer of detail, Griffith further 
showed that the capsule type acquired by the live pneumococcal strain after 
injection was always the capsule type of the heat-killed strain, even if that 
capsule was a different type from the parental live strain. Avery and 
colleagues built upon these observations and were able to reconstitute the 
transformation reaction in vitro (3, 61, 62, 246). In their landmark paper 
Avery, MacLeod, and McCarty provided definitive evidence that DNA was the 
material responsible for the phenotypic changes observed during bacterial 
transformation (14). This was the first demonstration that a nucleic acid 
could have biologic functions and these findings eventually gave rise to the 
field of molecular genetics.   
 In addition to aiding our understanding of fundamental biology, 
research involving the pneumococcus has also led to discoveries of great 
clinical importance. Shortly after the identification of the pneumococcus, 
Christian Gram published his technique for staining clinical tissue samples to 
aid in the identification of pathogenic organisms (93). Gram examined 
samples from the lungs of 20 patients who had died of pneumonia. In 19 of 
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the specimens he observed cocci that had not decolorized after aniline-
gentian violet staining (272), making S. pneumoniae the first identified 
Gram-positive organism. Interestingly, in the one sample that had no Gram-
positive bacteria, Gram observed a bacterium that was readily decolorized 
(Gram-negative), which is known today as Klebsiella pneumoniae. The 
significance of this finding was not initially fully appreciated, resulting in 
confusion about which organism was the true etiologic agent, though the 
roles of both K. pneumoniae and the pneumococcus as causes of pneumonia 
were eventually established (9). Nevertheless, Gram staining remains to this 
day a primary means of pathogen identification in the clinical microbiology 
laboratory. 
 The pneumococcus was also used in the first demonstration of 
antibiotic resistance. In the beginning of the 20th century, researchers 
observed that S. pneumoniae was sensitive to the quinine derivative 
ethylhydrocupreine, also known as optochin, while similar bacterial species 
were not (187). As part of this work, mice were infected with the 
pneumococcus and then experimentally treated with optochin. The 
investigators rapidly isolated pneumococci that had developed resistance to 
optochin (186). This experiment is additionally noteworthy as it is one of the 
first examples of using a specific compound to treat an infection (272). 
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Treatment and Vaccination 
Early treatment for pneumococcal disease was based on findings from 
studies conducted in rabbits at the end of the 19th century. In these 
experiments it was observed that serum from rabbits previously infected with 
pneumococci could protect against a secondary challenge with the same 
bacterial strain (141). Later, it was established that the pneumococcal 
capsular polysaccharide was the antigen responsible for this seroreactivity 
(103), making it the first non-protein antigen to be identified (272), antisera 
could be separated by strain type. The method of typing pneumococcal 
strains used well into the 20th century, known as the Quellung reaction (199), 
involves incubating pneumococci with the specific antisera. The reaction is 
monitored for bacterial agglutination and swelling of the capsule, which 
occurs only when the strain and antisera are of the same type. Once strains 
could be reliably serotyped, patients with pneumococcal disease were 
successfully treated through passive immunization with sera raised in horses 
(80).  
The success of serotherapy and development of antibiotics may have 
actually delayed advances in the development of a vaccine for the 
pneumococcus (272). The first vaccines against S. pneumoniae 
demonstrated that inoculation of purified capsule alone could generate 
protective immunity  (76, 79, 159, 248) and that multiple polysaccharide 
types inoculated at once were also effective (104, 134). These early vaccines 
were removed from the market due to low usage (12) and were only 
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revisited decades later as a result of the work of Robert Austrian. 
Austrian developed a 14-valent capsule vaccine and demonstrated its 
efficacy in preventing pneumococcal pneumonia (10, 13). The 14-valent 
vaccine was introduced in 1977 and eventually expanded in 1983 to include 
23 capsule types (230). Today this is still the broadest coverage of any 
pneumococcal vaccine. However, the capsule vaccine had limited success in 
protecting children due to lack of immunogenicity (172). 
 Following the introduction of the 7-valent pneumococcal conjugate 
vaccine (PCV7) in the US in 2000, rates of both invasive pneumococcal 
disease and pneumonia decreased dramatically (28, 94). This success was 
due in large part because the vaccine is efficacious in young children, the 
demographic most likely to contract pneumococcal disease (44). Similar 
declines in pneumococcal-attributed childhood illnesses were also observed 
internationally (70, 123), including in developing countries (43, 52, 92). This 
is noteworthy because the relative distribution of pneumococcal serotypes 
varies with geographic location (176) and PCV7 targeted the seven most 
common serotypes in the developed world (249). Serotype coverage 
expanded with introduction of the 13-valent conjugate vaccine (PCV13) in 
2010 (201), however this still represents only a fraction of the known 
pneumococcal serotypes that cause disease. In the years following vaccine 
introduction, researchers observed that non-vaccine seroptypes began to 
circulate more frequently in the population (1, 107), a phenomenon known 
as ‘serotype replacement.’ The degree to which serotype replacement 
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threatens to undermine the advances that vaccination has made against 
pneumococcal disease is a subject of debate (30, 155), though current next-
generation pneumococcal vaccines are focused on providing broader serotype 
coverage (90, 158, 290), ideally at lower cost (183). This is critical, as 
majority of the deaths attributed to pneumococcal disease today occur in the 
developing world (152, 202, 283). 
 Despite the success of the polysaccharide and conjugate vaccines, 
there were still an estimated 33,500 cases of invasive pneumococcal disease 
and 3,500 deaths due to S. pneumoniae infection in the U.S. in 2013 (44). 
The current treatment for pneumococcal infection is antibiotic therapy and 
like many other pyogenic bacteria, the development of antibiotic resistance 
remains a pertinent issue. The first patient to show clinical improvement 
from penicillin treatment was suffering from pneumococcal conjunctivitis 
(272) and the use of this antibiotic, as well as other β-lactams, remains 
common today. However, within a couple decades of widespread usage, 
penicillin-resistant pneumococci had been isolated clinically (100, 101). Rates 
of antibiotic resistance, specifically to penicillin, increased to over 25% in the 
U.S. (108), although evidence suggests that introduction of the 
pneumococcal conjugate vaccine has reduced levels of antibiotic resistance 
(53, 136).  
The years following conjugate-vaccine introduction also saw decreased 
pneumococcal disease in the elderly (94), a population that had not received 
either PCV7 or PCV13. This ‘herd immunity’ - protection of an unvaccinated 
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portion of the population - is attributed to the ability of the conjugate-vaccine 
to reduce the carrier state in children (54, 180). Animal models have 
demonstrated that this decrease in carriage is due to vaccine-induced 
antibody blocking the acquisition of the pneumococcus in the upper 
respiratory tract (232). The ability of the conjugate-vaccine to confer herd 
immunity underscores a critical aspect of the pneumococcus’ lifestyle - 
colonization and carriage in the hosts’ nasopharynx. 
 
 
Pneumococcal Nasopharyngeal Colonization 
 Streptococcus pneumoniae serially colonizes the nasopharynx of 
healthy humans. Colonization results in a suppurative rhinitis that is 
characterized by increased mucus secretion. Recent animal studies have 
demonstrated that these secretions are important for pneumococcal growth 
(247) and are also believed to contribute to transmission (66, 228, 244). 
Humans are the only natural host for pneumococci, and epidemiologic studies 
show that transmission increases in high-density populations, such as 
daycare centers, nursing homes, prisons, or within households (110, 177, 
193, 200, 224). Until recently there were no tractable animal models of 
pneumococcal transmission. The current model of pneumococcal 
transmission relies on viral co-infection with Influenza A (66) and it appears 
that the inflammation induced by viral infection is critical for transmission to 
occur (244). Although this model has advanced our understanding of 
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transmission, this aspect of pneumococcal pathogenesis remains vastly 
understudied. 
 Colonization events can occur as early as the first day of life, with the 
highest rates of carriage in children under the age of 2 (29). In this 
population, the rate of colonization is estimated at 20-50% (29), though 
some studies have reported carriage rates as high as 90% (71). Rates of 
colonization decrease with increasing age (156) and in adults carriage is 
estimated to be below 20% (29). Individuals can be colonized with multiple 
distinct pneumococcal strains at the same time (8, 37). 
Following the establishment of colonization, pneumococci are 
subsequently cleared from the upper respiratory tract by the hosts’ immune 
system. Clearance generally occurs over a period of a few weeks to a month 
(173). However, colonization with the same serotype for a duration lasting 
years has been reported (273). Nevertheless, this immune response is 
unable to confer protection to the host and individuals may be re-colonized 
throughout their lifetime.  
 
 
Virulence Factors 
The pneumococcus expresses several virulence factors that promote 
its survival and growth in the human host. The nasopharynx is the site of 
evolutionary pressure for S. pneumoniae; therefore, these factors generally 
promote colonization and persistence, usually by mechanisms of immune 
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evasion. However, they can also exacerbate disease processes, although 
disease in the host is relatively rare and has no evolutionary benefit for the 
bacterium (276). 
 
Capsule 
The capsular polysaccharide (Fig. 1.1), commonly referred to simply as 
‘capsule,’ is comprised of long alternating sugar chains that are covalently 
linked to the bacterial cell wall (256). This thick, sometimes mucoid (284), 
‘sugar coating’ functions as a protective barrier between the bacterial cell and 
the environment of the upper respiratory tract and is critical for successful 
colonization of the nasopharynx (161).  
Pneumococci of the same strain vary in the amount of capsule that 
they express, a phenomenon known as phase variation (138, 277). Bacteria 
that express high levels of capsule are called ‘opaque,’ a reference to their 
colony morphology, whereas variants with a low abundance of capsule are 
deemed ‘transparent.’ High levels of capsule expression aid in evasion of the 
host immune system by preventing complement deposition on the bacterial 
cell surface (119) and opsonophagocytic killing by phagocytes (137). Opaque 
variants are favored during invasive disease (138), while transparent 
variants are favored during colonization (277). Capsule can also prevent the 
action of antibiotics that target pneumococcal cell wall enzymes, presumably 
by blocking the ability of the antibiotic to penetrate to the cell surface (78).  
There are over 90 known capsule types (106), which define the 
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serotypes of pneumococci. The majority of capsules are negatively charged 
(130), a feature that allows the pneumococcus to repel the negatively 
charged mucus layer of the respiratory tract and prevents its clearance by 
mucociliary beating (197). Some serotypes are more commonly associated 
with invasive disease and differences in capsule type may contribute to the 
site of infection (126) and overall prevalence in the population (275), though 
this remains poorly characterized. 
 
Pneumolysin 
 The pneumococcus expresses a single pore-forming toxin named 
pneumolysin, which is a member of the cholesterol dependent cytolysin 
(CDC) family. Pneumolysin is expressed as a 53-kDa monomer that 
oligomerizes to form pores in cholesterol containing membranes (185, 270). 
These pores can be up to 30 nm in diameter (144) and at high 
concentrations can cause eukaryotic cell lysis (245). The CDC toxin family 
spans more than 20 bacterial species and all CDC toxins have a highly 
conserved tryptophan-rich undecapeptide region, which is critical for toxin 
insertion into host membranes (235, 265). In the case of pneumolysin, a 
single residue mutation in the undecapeptide results in near complete loss of 
toxin function (144), though binding to cholesterol occurs through residues 
outside of the undecapeptide region (73).  
 Pneumolysin is unique among the CDC toxin family because it lacks an 
N-terminal secretion signal sequence (270). It is known to be associated with 
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the bacterial cell wall (218, 219), though the exact mechanism of its release 
is still not well defined. It was originally believed that pneumolysin secretion 
was dependent on bacterial autolysis (181). However, pneumococcal strains 
lacking LytA – the autolytic amidase – are still able to secrete pneumolysin 
(15). Pneumococcal degradation by the host enzyme lysozyme, which 
hydrolyzes the glycan backbone of peptidoglycan, can cause the release of 
pneumolysin in broth culture (60).  
Nearly all clinically isolated strains of pneumococci express 
pneumolysin (131), underscoring its important role in disease, as well as its 
evolutionary  importance to the bacterium. Pneumolysin induces 
inflammation at the mucosal surface, though how this contributes to the 
organisms’ virulence appears to vary by site of infection or pneumococcal 
strain (126, 205). Pneumolysin-deficient strains are highly attenuated in 
multiple disease models (22, 23, 31, 236). Somewhat paradoxically, 
pneumolysin does not promote the establishment of nasopharyngeal 
colonization (237) and pneumolysin expression drives host clearance of 
colonization (171, 267). A mutated strain containing a full deletion of the 
pneumolysin gene has prolonged carriage in the nasopharynx compared to 
the isogenic wild type strain (171, 267) and exactly how pneumolysin 
contributes to the persistence of S. pneumoniae in the host or the population 
remains an open question. 
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Other Virulence Factors 
Although capsule is the immunodominant pneumococcal antigen, the 
pneumococcal surface protein A (PspA) can elicit cross-reactive antibodies 
(33). Vaccination with PspA can confer protection against pneumococcal 
colonization (204), pneumonia (34), and sepsis (255) in murine models. 
PspA is under active investigation as a potential vaccine target (194) because 
it is abundantly expressed in all pneumococcal strains and could offer 
broader strain coverage than is currently available. PspA prevents the 
deposition of complement onto the bacterial cell surface (226, 227, 264) by 
competitively inhibiting the binding of C-reactive protein (CRP) (190). 
Phosphocholine (ChoP), the moiety that is targeted by CRP, anchors the 
choline binding proteins, including PspA, to the bacterial cell surface (81, 
288). Prevention of CRP binding promotes virulence in sepsis models by 
inhibiting the alternative pathway of complement activation (227, 264). PspA 
also binds lactoferrin (99, 102), a glycoprotein that sequesters iron, as well 
as apolactoferrin (242), an iron-free form of lactoferrin. Apolactorferrin has 
bactericidal properties and binding by PspA promotes pneumococcal survival 
(242). It is speculated that PspA-mediated interactions with lactoferrin 
promote iron scavenging by S. pneumoniae, though whether this contributes 
to bacterial growth in vivo has not been resolved. 
Similar to many other bacterial pathogens and residents of the 
mucosal flora (32, 85, 86, 143, 188, 214, 215, 217), S. pneumoniae 
expresses a protease that specifically cleaves human immunoglobulin A1 
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(IgA1) (271). Evasion of this host immunoglobulin in the upper respiratory 
tract is critical for bacterial persistence, as IgA1 comprises over 90% of the 
mucosal IgA (140). The pneumococcal IgA1 protease cleaves the hinge 
region of IgA1, separating the FC domain from the antigen-binding Fab 
fragments. This protease promotes bacterial adherence (278) and prevents 
complement deposition and opsonophagocytic killing in vitro (74), though its 
specificity for human IgA1 has made in vivo animal studies challenging. 
Recently, however, experiments using mice passively immunized with 
monoclonal human IgA1 demonstrated that IgA1 protease promotes 
pneumococcal colonization in vivo (124).  
Pneumococcal strains express up to three neuraminidases (211), 
which cleave terminal sialic acid residues from mucins and cell surface 
glycans in the upper respiratory tract. These neuraminidases promote 
colonization in the nasopharynx (165, 262) by liberating nutrients for 
bacterial growth (247) and possibly exposing surface receptors required for 
adherence to the epithelial surface (210). S. pneumoniae also alters its cell 
wall structure to enhance resistance to the host muramidase lysozyme, which 
is abundantly expressed on the mucosal surface (49). This modification is 
energetically costly, but provides an advantage for colonizing organisms 
(59), although the pneumococcus still remains susceptible to lysozyme 
degradation by phagocytes (60). 
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Immune recognition of S. pneumoniae colonization 
A well-defined murine model of S. pneumoniae nasopharyngeal 
carriage (174), in which unanesthetized mice are intranasally inoculated with 
pneumococci to restrict bacterial colonization to the upper respiratory tract, 
has allowed us to further characterize both the host and bacterial factors that 
contribute to the dynamic process of colonization in the nasopharynx. This 
model has been validated by experimental human carriage studies with the 
same pneumococcal strain (173) and has contributed specifically to the 
elucidation of the host immune cell populations that respond to 
pneumococcal colonization and lead to eventual bacterial clearance. 
 
Neutrophils 
 Neutrophils are professional phagocytic cells that are critical in host 
defense against bacterial and fungal infections. During S. pneumoniae 
colonization, neutrophils are recruited to the upper respiratory tract early in 
infection, with peak influx generally between one and three days after 
bacterial inoculation (197, 291). They can be visualized by microscopy in the 
lumen of the nasopharynx, where they are associated with pneumococci 
(127). The ability of neutrophils to phagocytose and kill S. pneumoniae has 
been examined ex vivo and these studies have demonstrated that bacterial 
uptake is promoted by opsonization with anti-pneumococcal antibody that 
facilitates complement deposition (35). S. pneumoniae expresses a 
deoxyribonuclease  that confers resistance to killing by neutrophil 
! 16!
extracellular traps (NETs) (20). Instead, bacterial killing by neutrophils is 
dependent on the action of serine proteases following phagocytosis (251).  
 Neutrophil numbers in the nasopharynx wane shortly after the 
establishment of colonization (291). Their influx has minimal impact on 
bacterial numbers in the upper respiratory tract (171, 291), indicating that 
they are insufficient to effectively remove the pneumococcus from its niche 
before type-specific antibody develops. Nevertheless, depletion of neutrophils 
during colonization with an invasive pneumococcal strain significantly 
increases mortality in a mouse model (171), suggesting that although they 
do not promote clearance of nasal carriage, neutrophils are critical for host 
protection from invasive disease. 
 
Macrophages 
During S. pneumoniae colonization macrophages are recruited to the 
upper respiratory tract following initial influx of neutrophils. Their presence 
peaks by day five post colonization and is maintained for the duration of 
carriage (60, 291). Depletion of these macrophages through intranasal 
administration of clodronate lipososmes results in higher bacterial burden 
and a significantly longer duration of colonization (291), demonstrating their 
importance for effective bacterial clearance.  
Host expression of the C-C chemokine receptor type 2 (CCR2), which 
is present on the surface of inflammatory monocytes, is also required for 
proper macrophage recruitment. Mice that are deficient in CCR2 expression 
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(Ccr2-/-) have significantly lower numbers of nasopharyngeal macrophages 
over the duration of a colonization event (60), which results in an increased 
and sustained burden of pneumococci. The C-C chemokine ligand 2 (CCL2) 
binds CCR2 with the highest affinity of any CCR2 ligand (280) and further 
investigation showed that CCL2 is produced by macrophages in vitro 
following infection with pneumococci (60). Furthermore, these studies 
demonstrated that CCL2 production is dependent on bacterial expression of 
the pore-forming toxin pneumolysin, as well as host expression of the 
muramidase lysozyme.  
Similar to neutrophils, macrophages kill S. pneumoniae through 
phagocytosis and degradation. Although opsonization and complement 
deposition promote pneumococcal uptake (56), macrophages are able to 
phagocytose pneumococci in the absence of these components, through 
scavenger receptor-mediated binding to the bacterial surface. Expression of 
the scavenger receptor SR-AI/II on alveolar macrophages protects against 
pneumococcal pneumonia by facilitating bacterial up-take (7). Additionally, 
the scavenger receptor macrophage receptor with collagenous structure 
(MARCO) is important in host defense against both pneumonia and S. 
pneumoniae colonization (6, 67).  
Following uptake, pneumococci localize to the phagosome (91), which 
rapidly acidifies (139, 286), resulting in bacterial death (125). Nitric oxide 
production is important for S. pneumoniae killing by macrophages (167), 
although contributions of additional factors, such as proteases and other 
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degradative enzymes, has not been reported.  
 
Humoral Immune Responses 
 The successes of serotherapy and the pneumococcal vaccines clearly 
demonstrate that high titers of anti-pneumococcal antibodies can protect 
against disease. Patients with genetic mutations impairing development of 
antibodies are more susceptible to pneumococcal infection (150), further 
indicating an important role for antibody-mediated protection, which is 
believed to be due to increased opsonophagocytic killing by neutrophils (35). 
Antibodies induced by vaccination can reduce host susceptibility to 
colonization (54, 180) and studies of experimental human carriage have 
shown that higher antibody titers correlate with lower pneumococcal 
numbers in the nasopharynx (173). 
 Colonization results in the production of both IgA and IgG antibodies 
that detect the pneumococcal capsule and surface proteins (60, 173, 174, 
231, 233). Although antibody can block the acquisition of colonization (232), 
humoral responses are insufficient to clear pneumococci from an already 
colonized host (174) and natural immunity to S. pneumoniae colonization 
occurs independent of serotype (156), suggesting that other adaptive 
immune responses are required to achieve clearance. 
 
Cellular Immune Responses 
 HIV-positive individuals are more susceptible to pneumococcal disease 
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and lower CD4+ cell counts correlate with increased risk of infection (68), 
indicating that cellular immunity is critical for protection in the human host. 
Effective clearance of pneumococcal colonization in a murine model requires 
immunity acquired through CD4+ T-cells (106, 164), which is attributable 
specifically to the interleukin-17a (IL-17a) producing Th17 sub-population of 
CD4+ T-cells (130, 164, 291). Depletion of these cells during primary 
colonization prolongs bacterial carriage and dampens host responses to a 
secondary colonization event (291). These defects correlate with reduced 
numbers of macrophages and neutrophils during primary and secondary 
colonization, respectively (291). 
 
 
Innate Immune Detection of S. pneumoniae 
Hosts, from Drosophila to humans, express a finite set of genetically 
encoded ‘pattern recognition receptors’ (PRRs) (257). These receptors are 
highly expressed in cells of the innate immune system and detect conserved 
bacterial and viral motifs commonly called pathogen associated molecular 
patterns (PAMPs). PAMPs range from nucleic acids to secretion systems and 
host recognition of these signatures activates pro-inflammatory signaling 
cascades that drive innate immune defense. PRRs can broadly be classified 
by cellular localization and include the membrane-bound Toll-like receptors 
(TLRs) and C-type lectin receptors (CLRs), as well as the cytosolic Nod-like 
receptors (NLRs), AIM2-like receptors (ALRs), and (RIG)-I-like receptors 
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(RLRs). 
 
Extracellular Receptors 
The TLRs sample the extracellular milieu encountered by host cells. 
They sense a diversity of bacterial and viral ligands and their activation 
results in signaling cascades that drive pro-inflammatory cytokine 
production. All TLRs, except for TLR3, employ myeloid differentiation primary 
response gene 88 (MYD88) as an adaptor molecule for signaling. Humans 
with mutations in either MYD88 or interleukin-1 receptor-associated kinase 4 
(IRAK-4), a downstream kinase involved in TLR signaling, are acutely 
susceptible to pneumococcal disease (21, 213). Studies investigating the 
association of pneumococcal disease with polymorphisms in individual TLRs 
have yielded inconsistent findings (182, 260), suggesting a possible 
redundancy with other innate immune pathways that signal through MYD88 
and IRAK-4. 
 Pneumococcal lipoproteins and lipoteichoic acid activate TLR2 both in 
vitro (18, 240, 261) and in the respiratory tract epithelium during S. 
pneumoniae colonization (291). Mice deficient in TLR2 (Tlr2-/-) have 
increased susceptibility to invasive pneumococcal disease (19) that may be 
attributable to disruption of the epithelial barrier (19, 47), which allows 
greater access to the bloodstream and other sterile sites. Tlr2-/- mice also 
have prolonged bacterial carriage and reduced numbers of macrophages 
recruited to the nasopharynx (291). There are reports that TLR2 is activated 
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by peptidoglycan from Gram-positive bacteria (241, 287), though the 
veracity of this observation remains a matter of debate (263).  
 TLR4, which is classically activated by the lipopolysaccharide (LPS) of 
Gram-negative bacteria, is also reported to directly recognize the 
pneumococcal pore-forming toxin pneumolysin and protect against bacterial 
infection (162, 250). Others (2, 184, 267), however, have observed no effect 
of TLR4 in S. pneumoniae detection and the exact role of this TLR in 
recognition of pneumococci remains unclear. 
 In vitro studies have shown that TLR9, which recognizes CpG motifs 
within bacterial DNA (105), is activated upon S. pneumoniae infection with 
live, but not heat-killed, bacteria (184). Further investigations have defined a 
role for TLR9 activation in early defense against pneumococcal disease in 
vivo, however no effect on colonization has been observed (2).  
 
Intracellular Receptors 
 NLRs are a family of cytosolic PRRs that are characterized by a 
nucleotide oligomerization-binding domain (Nod) as well as C-terminal 
leucine-rich repeats, which are critical for ligand recognition and binding 
(122, 259). Nod1 and Nod2 detect bacterial peptidoglycan and trigger a 
signaling cascade that drives pro-inflammatory cytokine production through 
activation of the transcription factor nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB). Both Nod1 and Nod2 contain N-
terminal CARD domains, which facilitate signaling through homotypic CARD-
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CARD interactions with their common adaptor protein receptor-interacting 
protein 2 (RIP2) (24, 120, 121, 203). Nod 1 recognizes the meso-DAP motif 
of peptidoglycan from Gram-negative bacteria (87), as well a few select 
Gram-positive organisms, including Listeria and Bacillus species (45). Nod2 
detects the muramyl dipeptide (MDP) found in the cell wall of all bacterial 
species (88). 
 Nod2 detection of S. pneumoniae peptidoglycan during colonization 
contributes to macrophage driven bacterial clearance (60). In vitro studies 
have shown Nod2-dependent production of pro-inflammatory cytokines, 
including interleukin-6 (IL-6) and CCL2, following incubation with 
pneumococci (60). In vivo, host expression of CCR2, the receptor for CCL2, 
is required for increased macrophage presence in the nasopharynx, as well 
as subsequent bacterial clearance. In these studies, increased cytokine levels 
were dependent on host expression of lysozyme and bacterial production of 
pneumolysin (60), implicating a role for bacterial degradation and toxin 
release.  
Intracellular bacterial pathogens use a variety of strategies to access 
the cytosol. These mechanisms may provide insight into how pneumococcal 
products transit into the host cell cytosol (Fig. 1.2). Unlike the model 
intracellular organisms Listeria monocytogenes, which escapes from the 
phagosome into the cytosol (216), or Salmonella, which replicates inside a 
cellular vacuole (268), S. pneumoniae is killed and degraded following 
phagocytosis. However, all of these microbes activate intracellular host PRRs 
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(60, 268). L. monocytogenes uses its CDC toxin to perforate and destabilize 
the phagosome membrane, allowing intact bacteria to access the cytosol 
where they replicate and spread to other cells (216). Salmonella uses a type 
III secretion system to inject effector proteins into the cytosol, which 
remodel the phagosome to transform it into a hospitable replicative niche. S. 
pneumoniae has no known specialized secretion system, but it does express 
pneumolysin. It is possible the pneumolysin facilitates transit of bacterial 
components across the phagosome membrane, however, the exact 
mechanism by which pneumococcal cell wall components access the host cell 
cytosol to activate Nod2 remains unclear. 
A subset of NLRs and ALRs trigger a defense mechanism known as 
inflammasome activation. When this type of defense occurs an 
inflammasome complex, comprised of receptors and adaptor proteins, 
oligomerizes in the cytosol, causing activation of caspases 1 and 11 (149). 
The maturation of caspases 1 and 11 into their enzymatically active forms 
leads to the production of mature interleukin-1 beta (IL-1β) and interleukin-
18 (IL-18), ultimately resulting in the pro-inflammatory death of the host cell 
(51, 148, 169). Caspase-11 is activated by the acylated lipid A of LPS (98, 
137), and therefore detects many intracellular Gram-negative bacterial 
pathogens (36, 41, 42, 221). 
 Caspase-1 maturation can result from the activation of a variety of 
receptors, which detect a diversity of conserved virulence patterns including 
cytosolic flagellin (4, 83, 178), DNA (77, 114, 192), bacterial secretion 
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systems (179), and membrane damage (148, 191). S. pneumoniae was first 
characterized to activate the NLRP3 inflammasome (175) and subsequent 
study revealed that it also activates the AIM2 inflammasome  (72). Although 
they recognize different stimuli, both the NLRP3 and AIM2 inflammasomes 
assemble through the homotypic interactions of pyrin domains (PYD) at their 
N-termini with the PYD of the adapter molecule apoptosis-associated speck-
like protein containing a CARD (ASC). ASC then recruits procaspase-1 
through interactions between its caspase activation and recruitment domain 
(CARD) and the CARD domain of caspase-1. Recruitment of caspase-1 to this 
complex results in its activation (238), through what is believed to be an 
auto-processing mechanism similar to activation of caspases 8 and 9 during 
intrinsic and extrinsic apoptosis (229), although this has not yet been 
formally demonstrated.   
Activation of the NLRP3 inflammasome by S. pneumoniae occurs in 
multiple cell types including macrophages (72, 282), dendritic cells (175), 
and neutrophils (133) and is dependent on bacterial expression of 
pneumolysin. Incubating recombinant pneumolysin with host cells in vitro 
results in NLRP3 dependent pro-inflammatory cell death (175), presumably 
through action of the toxin at the plasma membrane. In contrast, when 
phagocytes are infected with live bacteria, NLRP3 and AIM2 mediated cell 
death is dependent on both bacterial uptake and expression of pneumolysin 
(72). This suggests that in the context of infection with the entire organism, 
rather than just its toxin, delivery of inflammasome activating ligands does 
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not occur across the plasma membrane.  
The role of inflammasome activation and subsequent IL-1β secretion 
during in vivo infection has only been partially addressed. Mice deficient in 
the NLRP3 receptor or ASC adaptor protein had increased bacterial burden 
and decreased survival in a pneumococcal pneumonia model (72, 175). 
Similar results were also observed in a model of pneumococcal corneal 
infection (133). Whether inflammasome activation occurs during 
pneumococcal colonization and promotes host defense remains to be 
explored. Given that the pneumococcus activates other cytosolic sensing 
systems and carriage induces inflammation, it is plausible that IL-1β 
secretion occurs during colonization and may contribute to eventual bacterial 
clearance. 
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Figure 1.1. Streptococcus pneumoniae morphology. 
(A) Electron micrograph of the type 23F S. pneumoniae strain used in these 
studies. Black arrow indicates the capsular polysaccharide (‘capsule’). Scale 
bar represents 500 nm.  
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Figure 1.2. Bacterial strategies to access the cytosol. 
(A) The intracellular bacterial pathogens Listeria monocytogenes and 
Salmonella use pore-forming toxins and secretion systems respectively, to 
gain access to the host cell cytosol to promote their survival. S. pneumoniae, 
in contrast, is killed and degraded, although it activate cytosolic pattern 
recognition receptors, suggesting cytosolic access occurs during infection.
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Aims of Dissertation 
The work presented in this dissertation was designed to address the following 
aims: 
1) To determine the mechanism by which S. pneumoniae products access the 
host cell cytosol during infection of macrophages 
Previous studies from our lab have defined a critical role for 
macrophages in the clearance of pneumococci from the host nasopharynx. 
This macrophage influx is dependent on Nod2 recognition of intracellular 
pneumococcal peptidoglycan, which triggers the expression and secretion of 
the macrophage chemokine CCL2. Production of CCL2 by macrophages in 
vitro is dependent on bacterial expression of the pneumococcal pore-forming 
toxin, pneumolysin. Pneumolysin can be released following bacterial lysis by 
the host muramidase lysozyme. Together these data suggest that cytosolic 
access occurs following phagocytosis and lysozyme-mediated bacterial 
degradation that releases pneumolysin, allowing transit of pneumococcal 
components across the phagosome membrane. Although signaling data 
support this hypothesis, quantification of pneumococcal components in the 
host cell cytosol remains to be formally demonstrated. 
To assess the mechanism of cytosolic access of pneumococcal 
components we adapted a detergent-based cellular fractionation assay to 
measure levels of capsular polysaccharide in the host cell cytosol following 
infection. This allowed us to interrogate both the host and bacterial factors 
that contribute to intracellular detection of S. pneumoniae. 
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2) To determine the consequences of cytosolic access on S. pneumoniae 
nasopharyngeal colonization  
 In vitro studies from other investigators have demonstrated that 
infection of phagocytes with S. pneumoniae results in activation of cytosolic 
innate immune sensors other than Nod2, including multiple receptors 
involved in inflammasome signaling. A protective role for both inflammasome 
components and IL-1β, the pro-inflammatory cytokine produced during 
inflammasome activation, against pneumococcal disease has already been 
defined. However, the contribution of these cytokines to pneumococcal 
colonization and the host response to carriage has not been investigated. 
 To determine the possible effects of inflammasome-derived cytokines 
on pneumococcal colonization, we intranasally inoculated type 1 IL-1 
receptor-deficient mice (Il1r1-/-) and monitored both bacterial density and 
host cell infiltrate in the nasopharynx. We further employed quantitative RT-
PCR to characterize the chemokine profile of colonized Il1r1-/- mice, which 
may contribute to altered host responses during S. pneumoniae carriage.  
 
 
 !!
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CHAPTER II 
 
 
Degradation products of the extracellular pathogen 
Streptococcus pneumoniae access the cytosol  
via its pore-forming toxin 
 
 
 
 
 
 
 
 
 
 
 
 
 
The contents of this chapter were originally published as:  
Lemon JK, Weiser JN. 2015. Degradation products of the extracellular 
pathogen Streptococcus pneumoniae access the cytosol via its pore-forming 
toxin. mBio 6(1):e02110-14. 
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Abstract 
Streptococcus pneumoniae is a leading pathogen with an extracellular 
lifestyle, however, it is detected by cytosolic surveillance systems of 
macrophages.  The innate immune response that follows cytosolic sensing of 
cell wall components results in recruitment of additional macrophages, which 
subsequently clear colonizing organisms from host airways.  In this study, we 
monitored cytosolic access by following the transit of the abundant bacterial 
surface component capsular polysaccharide, which is linked to the cell wall. 
Using confocal and electron microscopy, we characterized the location of cell 
wall components in murine macrophages, and found that they are distributed 
outside of membrane-bound organelles. Quantification of capsular 
polysaccharide through cellular fractionation demonstrated that cytosolic 
access of bacterial cell wall components is dependent on phagocytosis, 
bacterial sensitivity to the host degradative enzyme lysozyme, and release of 
the pore-forming toxin pneumolysin. Activation of p38 MAPK signaling is 
important for limiting access to the cytosol, however ultimately these are 
catastrophic events for both the bacteria and the macrophage, which 
undergoes cell death. Our results show how expression of a pore-forming 
toxin ensures the death of phagocytes that take up the organism, although 
cytosolic sensing results in innate immune detection that eventually allows 
for successful host defense. These findings provide an example of how 
cytosolic access applies to an extracellular microbe and contributes to its 
pathogenesis. 
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Importance 
Streptococcus pneumoniae is a bacterial pathogen that is a leading 
cause of pneumonia. Pneumococcal disease is preceded by colonization of the 
nasopharynx, which lasts several weeks before being cleared by the host’s 
immune system. Although S. pneumoniae is an extracellular microbe, 
intracellular detection of pneumococcal components is critical for bacterial 
clearance. In this study, we show that following bacterial uptake and 
degradation by phagocytes, pneumococcal products access the host cell 
cytosol via its pore-forming toxin. This phenomenon of cytosolic access 
results in phagocyte death and may serve to combat the host cells 
responsible for clearing the organism. Our results provide an example of how 
intracellular access and subsequent immune detection occurs during infection 
with an extracellular pathogen. 
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Introduction 
Cytosolic detection of pathogen associated molecular patterns is a key 
event in host discrimination between commensal and pathogenic microbes. 
While cytosolic access is critical for the pathogenesis of intracellular bacteria, 
access to the cytosolic compartment by bacteria with an extracellular lifestyle 
remains poorly understood. One such pathogen that has been shown to 
activate cytosolic sensing is Streptococcus pneumoniae, a Gram-positive 
bacterium that serially colonizes the human upper respiratory tract (URT) 
and is a leading cause of bacterial pneumonia (202). Colonization of the 
upper airway precedes invasive pneumococcal disease (29) and is normally 
cleared by the host immune response within several weeks (173). A murine 
model of S. pneumoniae colonization has demonstrated that clearance of 
pneumococcal colonization requires a sustained presence of macrophages in 
the URT (291), similar to the observation that alveolar macrophages are 
critical for host defense in the lower respiratory tract (142).  
The macrophage driven clearance of colonizing pneumococci is 
dependent on host expression of the cytosolic Nod-like receptor Nod2 (60). 
Recognition of the cell wall component peptidoglycan by Nod2 activates NF-
κB signaling (88, 203, 259), resulting in expression of pro-inflammatory 
cytokines, including the monocyte chemoattractant protein CCL2 (or MCP-1). 
Macrophage recruitment to the URT, as well as subsequent bacterial 
clearance, is dependent on production of CCL2 in vivo and in vitro requires 
bacterial expression of the pneumococcal pore-forming toxin, pneumolysin 
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(60). 
Pneumolysin, a CDC toxin, is expressed as a monomer that 
oligomerizes to form a pore up to 30 nm in diameter in cholesterol containing 
membranes (144). Pneumolysin is unique among the CDC family of toxins in 
that it lacks an N-terminal secretion signal sequence (270), but bacterial 
degradation by the muramidase lysozyme can cause its release in broth 
culture (59). Host expression of lysozyme is also required for clearance of 
pneumococcal colonization (60), suggesting that release of pneumolysin 
following lysozyme degradation allows peptidoglycan to access the host cell 
cytosol, where it is sensed by Nod2, eventually resulting in CCL2 production 
and clearance of colonization. Pneumolysin has been shown to facilitate 
cytosolic access of cell wall from other bacterial species in epithelial cells for 
sensing by Nod1 (222), though the mechanism by which Nod2 activation 
occurs in phagocytes remains to be determined. 
Here we show that pneumococcal cell wall associated components 
escape into the cytosol of macrophages following phagocytosis and 
degradation. Access to the cytosol is mediated by the pore-forming toxin 
pneumolysin and is dependent on the ability of pneumolysin to bind host cell 
membranes. While the host cell has defenses to limit the amount of bacterial 
products that escape the phagosome, cytosolic access ultimately leads to the 
pro-inflammatory death of the macrophage. 
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Results 
Pneumococcal components access the cytosol of macrophages 
The process of cytosolic access was monitored by following the transit 
of the bacterial surface component capsular polysaccharide (CPS), which is 
covalently linked to the cell wall (256). CPS was chosen as a proxy for cell 
wall because it is abundant, long lived in the host cell, and easily detectable. 
To visualize pneumococcal fragments we incubated murine bone marrow 
derived macrophages (BMMs) with S. pneumoniae and, following 
phagocytosis and degradation, conducted immunofluorescence staining for 
the pneumococcal CPS and the phagolysosome marker, LAMP1. By confocal 
microscopy, we observed CPS staining within LAMP1-positive vesicles (Fig. 
2.1A, white open arrow), as well as smaller foci of CPS that do not co-localize 
with the phagolysosome marker (Fig. 2.1A, white closed arrows). To address 
whether these fragments were in other membrane-bound organelles, we 
conducted immuno-gold labeling and electron microscopy of BMMs incubated 
with pneumococci. We observed immuno-gold staining for CPS both within 
the phagosome and outside of any membrane-bound compartment by 45 
minutes after infection (Fig. 2.1C, red arrows). At three hours post-infection 
the bacteria appeared fully degraded, but gold labeling of CPS was still visible 
both within and outside the phagosome (Fig. 2.2). Uninfected macrophages 
had no detectable immuno-gold labeling for CPS (data not shown). These 
results suggest that pneumococcal products are present in the host cell 
cytosol following bacterial degradation by BMMs.  
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The amount of pneumococcal products in the cytosol was more 
precisely quantified by adaptation of a detergent based sub-cellular 
fractionation assay. Following infection with S. pneumoniae, BMMs were 
permeabilized with detergents to lyse either all host cell membranes or 
selectively lyse the plasma membrane. The resulting supernatants were 
ultracentrifuged to generate purified fractions representing either the cytosol 
or whole cell contents. The purity of these fractions was validated by western 
blotting for proteins present in either the cytosol (LDH) or lysosome 
(Cathepsin B) (Fig. 2.3A), and the amount of pneumococcal CPS in each 
fraction was quantified by ELISA. The percentage of CPS present in the 
cytosol fractions was calculated as a proportion of the CPS measured in the 
whole cell fractions and was significantly higher than background levels of 
contamination, which were determined by ELISA for the lysosome protein 
Cathepsin B (Fig. 2.3B). A S. pneumoniae strain lacking two cell wall 
modifying enzymes, making it hypersensitive to degradation by the host 
enzyme lysozyme (pgdA-/adr-) had significantly higher amounts of CPS in 
the cytosol fraction compared to a wild type (WT) pneumococcal strain (Fig. 
2.3B), though no difference in total bacterial uptake was observed between 
the two strains, as measured by CPS in the whole cell fractions (Fig. 2.3C). 
In a gentamicin protection assay, both the WT and the pgdA-/adr- strains 
were killed over a 30 minute infection, though this process was more rapid 
for the pgdA-/adr- mutant (Fig. 2.3D). BMM killing of the pgdA-/adr- mutant 
strain was largely lysozyme dependent (Fig. 2.3E), correlating with the lack 
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of intracellular signaling previously observed in lysozyme deficient BMMs 
(60). Since the pgdA-/adr- strain had significantly higher levels of CPS 
present in the cytosol compared to the WT strain, unless otherwise specified, 
subsequent experiments used this lysozyme sensitive S. pneumoniae mutant 
in order to interrogate the host and bacterial factors mediating access of 
pneumococcal cell wall products to the cytosol. 
 
Access to the cytosol is dependent on phagocytosis and pneumolysin 
To address the role of bacterial uptake in cytosolic access of 
pneumococcal cell wall components, we treated BMMs with cytochalasin D 
(CytD), an inhibitor of actin polymerization, to block phagocytosis. Following 
infection with S. pneumoniae (Spn), the presence of CPS in the whole cell 
fractions of host cells was blocked by incubation with CytD (Fig. 2.4A). The 
presence of CPS in the cytosol fractions upon infection with pneumococci was 
similarly dependent on bacterial uptake (Fig. 2.4B). These results 
demonstrate that cytosolic access of pneumococcal CPS requires 
phagocytosis. 
The pneumococcal pore-forming toxin, pneumolysin, is required for 
activation of cytosolic host signaling pathways (60). The role of pneumolysin 
in cytosolic access of pneumococcal cell wall components was assessed by 
quantifying the amount of capsule present in the cytosol of BMMs infected 
with a lysozyme sensitive S. pneumoniae strain containing an unmarked, 
complete in-frame deletion of the pneumolysin gene (ply-). The absence of 
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pneumolysin had no effect on the ability of host cells to take up 
pneumococci, as seen by similar levels of CPS in the whole cell fractions (Fig. 
2.5A). However, compared to a bacterial strain expressing WT pneumolysin, 
the ply- mutant had significantly less CPS present in the host cell cytosol 
(Fig. 2.5B). The loss of pneumolysin expression had no effect on intracellular 
bacterial killing (Fig. 2.5C). A pneumococcal strain expressing a pneumolysin 
toxoid, containing alanine mutations in the two residues that bind cholesterol 
(plyTL→AA) (73), which is deficient in pore-formation as assessed by hemolysis 
assay (Fig. 2.6A), but has no defect in amount of pneumolysin protein 
expressed (Fig. 2.6B), similarly had significantly reduced levels of CPS in the 
cytosol fraction (Fig. 2.5B). Reintroduction of the pneumolysin gene to 
correct the mutation (ply+) fully restored the presence of CPS in the host cell 
cytosol (Fig. 2.5B). Together, these data show that pneumolysin and 
specifically toxin binding of the host-membrane are required for cytosolic 
access of pneumococcal cell wall components. 
 
Cytosolic access is independent of TLR4 and acidification and is attenuated by 
p38 MAPK activation 
Toll-like receptor 4 (TLR4) has been reported to aid in host defense 
through detection of pneumolysin (162). To determine the role of TLR4 in 
cytosolic access of pneumococcal products, we differentiated BMMs from 
C57BL/6 (WT) and Tlr4-/- mice, infected them with pneumococci, and 
quantified the presence of CPS by fractionation and ELISA. We observed no 
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difference in the amount of total bacterial capsule in the Tlr4-/- macrophages 
compared to WT macrophages (Fig. 2.7A) and there was no significant 
difference in the amount of CPS in the cytosolic fractions between WT and 
Tlr4-/- macrophages (Fig. 2.7B). Cytosolic access, therefore, occurs 
independently of TLR4 activation.  
Acidification of the phagosome occurs rapidly following bacterial 
uptake. Whether phagosome acidification is required for bacterial products to 
escape into the cytosol was ascertained by incubating BMMs with bafilomycin 
A (BAF), a specific inhibitor of the vacuolar ATPase. The ability of BAF to 
block acidification was validated by western blotting for a lysosomal protease 
which matures only at low pH (Fig. 2.8). Measurements of CPS showed no 
difference in total bacterial uptake (Fig. 2.7C) or the amount of capsule in 
the cytosol (Fig. 2.7D) between macrophages treated with BAF and untreated 
BMMs. These results show that cytosolic access of pneumococcal components 
is independent of phagosome acidification. 
P38 mitogen-activated protein kinase (MAPK) is an important factor in 
host defense against diverse bacterial pore-forming toxins (116, 118, 195) 
and is activated in a pneumolysin-dependent manner in both epithelial cells 
(223) and macrophages (58). To investigate whether p38 MAPK detection of 
pneumolysin affects cytosolic access, we treated BMMs with SB203580, an 
inhibitor of p38 MAPK activation (MAPKi), before infection with S. 
pneumoniae and sub-cellular fractionation. When p38 MAPK was inhibited in 
BMMs infected with wild type (WT) S. pneumoniae, we observed a significant 
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increase in the amount of CPS in the cytosol fraction (Fig. 2.9B), but no 
change in total capsule in the whole-cell fraction (Fig. 2.9A). Infection of 
MAPKi treated BMMs with the ply- strain showed no such increase in cytosolic 
CPS amounts, demonstrating that the hypersensitization observed during 
p38 MAPK inhibition is dependent on bacterial expression of pneumolysin 
(Fig. 2.9B). These results suggest that pneumolysin dependent activation of 
p38 MAPK limits the amount of pneumococcal CPS that accesses the cytosol 
during infection. 
 
Cytosolic access results in macrophage death 
The final fate of host cells following infection with S. pneumoniae was 
ascertained by incubating BMMs with a lysozyme sensitive (pgdA-/adr-) 
bacterial strain expressing pneumolysin or an isogenic ply- strain (pgdA-/adr-
/ply-), in the presence or absence of CytD, and measuring cytotoxicity by 
release of lactate dehydrogenase (LDH) at 24 hours after infection. BMMs 
infected with the pneumolysin-expressing mutant had significantly higher 
levels of cytotoxicity compared to BMMs infected with the isogenic ply- strain 
or those treated with CytD (Fig. 2.10A). These results were also observed 
upon infection of BMMs with the WT and its isogenic ply- bacterial strains 
(Fig. 2.10B). Addition of the p38 MAPK inhibitor prior to infection did not 
significantly alter macrophage cytotoxicity at 24 hours post-infection (Fig. 
2.11). These data show that macrophage death occurs following 
pneumococcal infection and is dependent on bacterial uptake and expression 
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of pneumolysin. 
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Discussion 
 Many Gram-positive pathogens express members of the CDC family, or 
other pore-forming toxins (265). These toxins have diverse functions 
including translocation of effectors by, for example, streptolysin O of 
Streptococcus pyogenes (160), or access to a replicative niche, as in the case 
of listeriolysin O (LLO) of Listeria monocytogenes (216). Unlike LLO, which 
allows viable bacteria to access the cytosol of host cells, for S. pneumoniae, 
it is bacterial contents following degradation and killing that transit into the 
cytosol.  
We (60) and others (115) have previously characterized Nod2-
dependent intracellular sensing of extracellular pathogens. In this study, we 
adapted a sub-cellular fractionation assay, coupled with detection of CPS by 
ELISA, to elucidate the mechanism by which cell wall components of the 
extracellular bacterium, S. pneumoniae, escape into the host cell cytosol. 
Here we visually and quantitatively demonstrate the transit of pneumococcal 
products in a manner that is dependent on lysozyme, bacterial uptake, 
pneumolysin, and specifically the ability of pneumolysin to bind and form 
pores in host membranes. Our results suggest a model in which S. 
pneumoniae is phagocytosed and degraded in the phagosome by lysozyme, 
which results in release of the pore-forming toxin pneumolysin and allows 
transit of bacterial components across the phagosome membrane to the 
cytosol where they can be detected by intracellular host receptors. Others 
have recently observed phagosome disruption at a later time-point post-
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infection, which is independent of pore-formation by pneumolysin (25), 
suggesting that there may be more than one mechanism of accessing the 
host cell cytosol. 
Lysozyme is abundantly expressed on both the mucosal surface (49) 
and within professional phagocytes (75). As a result, mucosal pathogens, 
including S. pneumoniae and L. monocytogenes, modify their peptidoglycan 
to confer increased resistance to this degradative enzyme (59, 220). 
However, these modifications confer only partial resistance because, 
complementary to previously observed in vitro data (59), pneumococcal 
killing by macrophages ex vivo is dependent on lysozyme, and modification 
to the bacterial cell wall delays, but does not block, bacterial killing. Our 
observation that cytosolic access does not require acidification of the 
phagosome is consistent with lysozyme-dependent pneumococcal 
degradation, which can occur in broth culture at a neutral pH (59). 
Previous work has characterized a role for pneumolysin in the transit 
of other bacterial species’ peptidoglycan across the plasma membrane of 
epithelial cells (222). While it is possible that lysed extracellular pneumococci 
could access the host cytosol in a similar fashion, our finding that access to 
the cytosol in professional phagocytes requires bacterial uptake and 
degradation suggests that the transit of pneumococcal cell wall components 
we observe occurs across the phagosome membrane, rather than the plasma 
membrane. Although we have not directly visualized bacterial contents 
passing through the pore made by pneumolysin, our results demonstrate 
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that the presence of pneumococcal products in the cytosol requires both 
toxin expression and function.  
P38 MAPK senses a diversity of bacterial toxins including proaerolysin 
(116) and streptolysin O (223), a cytolysin in the same toxin family as 
pneumolysin, and plays an important role in host defense. Activation of p38 
MAPK occurs rapidly upon incubation of S. pneumoniae with macrophages 
(58), making it likely that initial sensing occurs at the plasma membrane 
prior to phagocytosis. Furthermore, purified pneumolysin is able to activate 
p38 MAPK (223) suggesting that detection of toxin activity is independent of 
host pattern recognition receptors present at the plasma membrane. Our 
data show that host cell sensing of pneumolysin by p38 MAPK is able to limit 
the transit of bacterial components to the cytosol, raising the possibility that 
MAPK activation may attenuate phagosomal damage. Similar observations 
have been made for Staphylococcus aureus α-toxin, in which p38 MAPK 
activation is required for cellular recovery, presumably through plasma 
membrane resealing (118). Lysosomal proteases have been shown to cleave 
pneumolysin (40), raising the possibility that host proteolysis of this pore-
forming toxin may be another mechanism to limit cytosolic access. Ultimately 
in the case of S. pneumoniae, these defenses are insufficient and cytosolic 
access proves fatal for the host cell. 
The observation that host cell death is dependent on bacterial uptake 
and pneumolysin raises the possibility that accessing the cytosol evolved as a 
mechanism to ensure death of the host cell that takes up the organism. In 
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the context of nasopharyngeal colonization, this may allow the 
pneumococcus to persist by limiting further clearance by the phagocytes that 
are killed. However, accessing the host cell cytosol results in Nod2-
dependent pro-inflammatory signaling, leading to further recruitment of 
phagocytic cells that aid in bacterial clearance. In addition to Nod2, S. 
pneumoniae is known to activate type I interferon signaling pathways (208) 
and the cytosolic NLRP3 and AIM2 inflammasomes (72) though strain-to-
strain variation has been observed (282). In these studies host cell death 
was dependent on both pneumolysin expression and bacterial uptake, 
making it likely that the cell death observed in our study is a result of 
inflammasome activation. Toxin-dependent activation of the NLRP3 
inflammasome and subsequent phagocyte death has also been described for 
other extracellular pathogens (97). While inflammasome signaling is 
important for host defense against pneumococcal pneumonia (72, 128, 282), 
the role of inflammatory cytokines such as IL-1β in nasopharyngeal 
colonization of S. pneumoniae remains to be defined.  
 Intracellular bacterial pathogens access the cytosol as part of their 
lifecycle through use of pore-forming toxins or specialized secretion systems 
(268). These virulence activities, however, expose pathogen associated 
molecular patterns to host receptors. Here we show that components of S. 
pneumoniae, a leading extracellular pathogen, access the cytosol via its 
pore-forming toxin, pneumolysin, following degradation and killing in the 
phagosome. Our results provide an example for how cytosolic access, and 
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subsequent intracellular innate immune detection, is relevant to a clinically 
important extracellular microbe. 
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Figure 2.1. Pneumococcal cell wall components access the cytosol of 
macrophages 
(A) Murine bone marrow derived macrophages (BMMs) were incubated with 
S. pneumoniae for 2.5 hours and stained for immunofluorescence with 
polyclonal anti-type 23F capsule sera (red, capsule), anti-Lamp1 antibody 
(green, phagosome), and DAPI (blue, DNA). 
(B and C) Electron microscopy of BMMs incubated with S. pneumoniae for 45 
minutes and immuno-gold labeled with IgG purified from polyclonal anti-type 
23F capsule sera. Original magnification, x600 (A), x25,000 (B), and x50,000 
(C).  
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Figure 2.2. Pneumococcal cell wall components access the cytosol of 
macrophages 
(A and B) Electron microscopy of BMMs incubated with S. pneumoniae for 3 
hours and immuno-gold labeled with IgG purified from polyclonal anti-type 
23F capsule sera. White arrows indicate gold-particles outside of organelles. 
Original magnification x15,000 (A) and x50,000 (B). 
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Figure 2.3. Quantification of pneumococcal products by cellular 
fractionation 
(A) Western blot of sub-cellular fractions from bone marrow-derived 
macrophages (BMMs) detecting cytosolic (LDH) and lysosome (Cathepsin B) 
protein.  
(B and C) Measurement of contents of cytosol fractions as a proportion of 
whole cell contents by ELISA. Purity of fractions was measured by Cathepsin 
B ELISA with dashed line indicating average level of contamination of 
cytosolic fractions. Quantification of capsular polysaccharide (CPS) in the 
cytosolic fractions (B) or whole cell fractions (C) of BMMs infected with wild 
type (WT) or lysozyme hypersensitive (pgdA-/adr-) S. pneumoniae. Values 
from 2-5 independent experiments, error bars represent ± SEM, One-way 
ANOVA with Newman-Keuls post test, *p < 0.05, ***p < 0.001; and ns, not 
significant.  
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Figure 2.3 Continued. 
(D and E) Gentamicin protection assay to measure intracellular killing of S. 
pneumoniae (Spn). BMMs were infected with Spn and treated with 300 
µg/mL gentamicin to kill extracellular bacteria. At the time points indicated, 
BMMs were lysed with water and serial dilutions plated for CFUs to quantify 
surviving Spn. C57BL/6 BMMs were infected with WT or pgdA-/adr- Spn 
strains (D) and BMMs from FVB/N or LysM-/- mice were infected with the 
lysozyme sensitive pgdA-/adr- Spn strain (E). Percentages were calculated as 
a proportion of CFUs from the 5 min time point, values from 2 independent 
experiments, error bars represent ± SEM, One-way ANOVA with Newman-
Keuls post test, *p < 0.05, ***p < 0.001; and ns, not significant. 
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Figure 2.4. Access to the cytosol is dependent on bacterial uptake 
(A and B) Measurement of pneumococcal capsular polysaccharide in whole 
cell (A) and cytosol (B) fractions of bone marrow derived macrophages 
(BMMs) by ELISA. Where indicated, BMMs were infected with lysozyme 
sensitive S. pneumoniae (Spn) and treated with 20 µM cytochalasin D (CytD) 
to block phagocytosis. In contrast to other figures, cytosolic fractions are not 
represented as a proportion of the whole fractions due to nearly undetectable 
levels of capsule in the CytD treated whole cell fractions. Values from 3 
independent experiments, error bars represent ± SEM, One-way ANOVA with 
Newman-Keuls post test, *p < 0.05, ***p < 0.001.  
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Figure 2.5. Pneumolysin is required for access to the host cell cytosol 
(A and B) Measurement of pneumococcal capsule in whole cell (A) and 
cytosol (B) fractions of bone marrow derived macrophages (BMMs) by ELISA. 
Where indicated, BMMs were infected with S. pneumoniae strains with wild 
type (WT) pneumolysin (Ply), complete deletion of the Ply gene (ply-), a 
toxoid Ply unable to bind cholesterol (plyTL→AA), and reintroduction of the full 
WT Ply gene (ply+). Dashed line indicates average level of contamination of 
cytosolic fractions (B). Values from 3-5 independent experiments, error bars 
represent ± SEM, One-way ANOVA with Newman-Keuls post test, *p < 0.05.  
B A 
C 
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Figure 2.5 Continued. 
(C) Gentamicin protection assay to measure intracellular killing of S. 
pneumoniae (Spn). BMMs were infected with lysozyme sensitive S. 
pneumoniae strains either deficient for pneumolysin (ply-) or expressing wild 
type (WT) pneumolysin. BMMs were treated with 300 µg/mL gentamicin to 
kill extracellular bacteria and at the time points indicated, were lysed with 
water and serial dilutions plated for CFUs to quantify surviving Spn. 
Percentages were calculated as a proportion of CFUs from the 5 min time 
point, values from 2 independent experiments, Student’s t-test, ns, not 
significant. 
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Figure 2.6. Validation of pneumococcal strains expressing 
pneumolysin mutations 
(A) Hemolysis assay to test for pneumolysin pore-formation. Horse red blood 
cells (RBC) were incubated with serially diluted lysates from S. pneumoniae 
expressing wild type (WT) pneumolysin, a pneumolysin-deficient strain (ply-
), a toxoid that is unable to bind cholesterol (plyTL→AA), or a corrected mutant 
strain (ply+), for 30 min. Lysis buffer alone was used as a negative control 
(NC). Unlysed RBCs were pelleted and imaged. Representative images shown. 
(B) Western blot for pneumolysin expression. Lysates from lysozyme 
sensitive S. pneumoniae strains were probed for expression of pneumolysin 
(Ply) or pneumococcal surface protein A (PspA) as a loading control. 
Representative images shown. 
NC 
WT 
ply- 
plyTL→AA 
ply+ 
Lysate Concentration 
A B 
Ply 
PspA 
WT ply- plyTL→AA ply+ 
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Figure 2.7. Cytosolic access is independent of TLR4 and acidification 
(A and B) Bone marrow-derived macrophages (BMMs) from C57BL/6 (WT) 
and Tlr4-/- mice were infected with S. pneumoniae and fractionated. Bacterial 
capsular polysaccharide (CPS) in the whole cell (A) and cytosol (B) fractions 
was measured by ELISA.  
(C and D) BMMs from WT mice were treated with 30 nM bafilomycin A (BAF) 
prior to infection with S. pneumoniae and sub-cellular fractionation. CPS in 
the whole cell (C) and cytosol (D) fractions was measured by ELISA. Values 
from 3 independent experiments, error bars represent ± SEM, Unpaired t-
test, ns, not significant. 
A B 
C D 
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Figure 2.8. Inhibition of phagosome acidification by bafilomycin A 
treatment 
(A) Whole cell fractions from S. pneumoniae infected macrophages untreated 
or pre-treated with 30 nM bafilomycin A (BAF) for 1 hour were probed for the 
lysosomal protein Cathepsin B or the cytosolic protein lactate dehydrogenase 
(LDH). Images from same blot in non-contiguous lanes. 
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Figure 2.9. Cytosolic access is attenuated by p38 MAPK activation 
(A and B) BMMs were infected with a S. pneumoniae strains expressing 
pneumolysin (WT) or a pneumolysin-deficient pneumococcal strain (ply-). 
Where indicated, BMMs were treated with SB203580, a specific inhibitor of 
p38 MAPK (MAPKi). Infected BMMs were fractionated and CPS was quantified 
by ELISA in the whole cell (A) and cytosol (B) fractions, dashed line indicates 
average level of contamination of cytosolic fractions. Values from 3-5 
independent experiments, error bars represent ± SEM, One-way ANOVA with 
Newman-Keuls post test, **p < 0.01***p < 0.001. 
A B 
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Figure 2.10. Cytosolic access results in macrophage death 
(A-B) Bone marrow-derived macrophages (BMMs) were infected with S. 
pneumoniae strains or left uninfected (Un). Where indicated, BMMs were 
treated with 20 µM cytochalasinD (CytD) to block phagocytosis. Supernatants 
were collected at 24 hours post infection. Cytotoxicity was measured by 
release of lactate dehydrogenase (LDH) in supernatants. BMMs were infected 
with a lysozyme sensitive (pgdA-/adr-) and an isogenic pneumolysin deficient 
(pgdA-/adr-/ply-) (A) or wild type (WT) and pneumolysin deficient (ply-) 
strains (B). Values are from 2-4 independent experiments, error bars 
represent ± SEM, One-way ANOVA with Newman-Keuls post test, ***p < 
0.001, ND, not detected. 
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Figure 2.11. Late macrophage death is not affected by prior p38 
MAPK inhibition. 
(A) Bone marrow-derived macrophages (BMMs) were infected with wild type 
(WT) or pneumolysin-deficient (ply-) S. pneumoniae strains or left uninfected 
(Un). Where indicated, BMMs were treated with SB203580, a specific 
inhibitor of p38 MAPK (MAPKi). Supernatants were collected at 24 hours 
post-infection and cytotoxicity was measured by release of lactate 
dehydrogenase (LDH). Values are from 2 independent experiments, error 
bars represent ± SEM, One-way ANOVA with Newman-Keuls post test, ***p < 
0.001, ND, not detected. 
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CHAPTER III 
 
 
Sensing of IL-1 cytokines during Streptococcus pneumoniae 
colonization contributes to macrophage recruitment  
and bacterial clearance 
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Abstract 
Streptococcus pneumoniae, a leading cause of bacterial disease, is 
most commonly carried in the human nasopharynx. Colonization induces 
inflammation that promotes the organism’s growth and transmission. This 
inflammatory response is dependent on intracellular sensing of bacterial 
components, which access the cytosolic compartment via the pneumococcal 
pore-forming toxin pneumolysin. In vitro, cytosolic access results in cell 
death that includes release of the pro-inflammatory cytokine IL-1β. IL-1 
family cytokines, including IL-1β, are secreted upon activation of 
inflammasomes, though the role of this activation in the host immune 
response to pneumococcal carriage is unknown. Using a murine model of 
pneumococcal nasopharyngeal colonization, we show that mice deficient in 
the interleukin-1 receptor type 1 (Il1r1-/-) have reduced numbers of 
neutrophils early after infection, fewer macrophages later in carriage, and 
prolonged bacterial colonization. Moreover, intranasal administration of Il-1β 
promoted clearance. Macrophages are the effectors of clearance and 
characterization of macrophage chemokines in colonized mice revealed that 
Il1r1-/- mice have lower expression of the C-C motif chemokine ligand 6 
(CCL6), correlating with reduced macrophage recruitment to the 
nasopharynx. IL-1 family cytokines are known to promote adaptive 
immunity. However, we observed no difference in the development of 
humoral or cellular immunity to pneumococcal colonization between wild type 
and Il1r1-/- mice. Our findings show that sensing of IL-1 cytokines during 
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colonization promotes inflammation without immunity, which may ultimately 
benefit the pneumococcus.  
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Introduction 
Streptococcus pneumoniae is an opportunistic bacterial pathogen that 
is responsible for over 1 million deaths annually, mostly in children under the 
age of five (283). The pneumococcus serially colonizes the mucosal surfaces 
of the human upper respiratory tract, and carriage of the organism provides 
the reservoir for all pneumococcal disease (29).  Colonization induces airway 
inflammation that is characterized by a suppurative rhinitis and increased 
mucus secretion.  These secretions promote bacterial growth (247) and 
inflammation is important for bacterial transmission in a viral co-infection 
model (244). Human studies have demonstrated that higher bacterial 
burdens are correlated with a more profound rhinitis (234). However, as a 
result of this inflammatory response, colonization is normally cleared by the 
host immune system within several weeks (173). 
 A well-defined murine model of pneumococcal colonization (174) has 
elucidated bacterial and host factors that are critical to immune recognition 
of the pneumococcus, which drives the eventual resolution of the carrier 
state. Although early colonization triggers the recruitment of neutrophils, 
these are ineffective at resolving the infection. Clearance of pneumococci 
from the upper airway over a period of weeks requires a sustained presence 
of macrophages in the nasopharynx (291). Although S. pneumoniae is an 
extracellular pathogen, this macrophage influx is the result of intracellular 
innate immune recognition by the cytosolic receptor Nod2 (60). Nod2 detects 
peptidoglycan (88, 259) that accesses the macrophage cytosol via the 
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pneumococcal pore-forming toxin, pneumolysin, following phagocytosis and 
bacterial degradation (151). Nod2 activation results in nuclear factor κB 
activation (203) and drives production of pro-inflammatory cytokines, such 
as CCL2, which contributes to macrophage dependent pneumococcal 
clearance (60). Cytosolic access, however, is a fatal event for the host cell 
following bacterial uptake (151). The type of cell death that occurs and its 
contribution to the host immune response remains unclear. 
 Our further in vitro studies show that macrophage death results in 
pneumolysin-dependent release of the pro-inflammatory cytokine IL-1β, 
indicating activation of the inflammasome. Inflammasomes are multi-protein 
cytosolic complexes that oligomerize through homotypic domain interactions 
and are comprised of a sensor, which detects bacterial stimuli, and adaptor 
proteins that recruit procaspase-1. This recruitment drives caspase-1 
enzymatic activation, which processes pro-IL-1β and pro-IL-18 into their 
mature forms and results in a pro-inflammatory cell death known as 
‘pyroptosis’ (51). 
The role of inflammasome activation and the production of IL-1 family 
cytokines in pneumococcal disease has been characterized (72, 128, 133, 
175). However, carriage rather than disease is the predominant state for 
pneumococci in the host. The contribution of pro-inflammatory cell death to 
immunity against this extracellular pathogen during colonization has not 
been determined.  Here we show that host sensing of IL-1 family cytokines in 
vivo is required for the macrophage presence in the nasopharynx and 
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clearance of pneumococcal colonization. IL-1 cytokine production in response 
to the pneumococcus contributes to inflammation in the upper airway, 
without driving the eventual development of adaptive immune responses.  
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Results 
Pneumococcal infection results in IL-1 family cytokine expression in vitro and 
in vivo 
We have previously reported that infection of macrophages with a type 
23F strain of S. pneumoniae results in host cell death, subsequent to 
bacterial uptake and pneumolysin-dependent cytosolic access of 
pneumococcal fragments (151). To determine whether pneumolysin-
dependent cytosolic access causes pro-inflammatory cytokine release upon in 
vitro infection, we incubated BMMs with the wild type 23F isolate (WT) and 
24 hours later assayed for the presence of IL-1β in the cell culture 
supernatants by Western blotting. We observed the release of mature IL-1β 
by BMMs infected with WT bacteria, but not in the supernatants of BMMs 
infected with an isogenic pneumolysin-deficient strain (ply-) (Fig. 3.1A). 
Furthermore, pre-incubation with CytD, an inhibitor of actin polymerization 
reduced the amount of IL-1β secreted, suggesting that pro-inflammatory 
cytokine production is dependent on bacterial uptake. Quantification by 
ELISA showed that release of IL-1β by BMMs was significantly reduced during 
infection with the ply- strain and when phagocytosis was blocked by CytD 
treatment (Fig. 3.1B). Additionally, enzymatic processing of caspase-1 and 
production of its active p10 fragment correlated with secretion of IL-1β (Fig. 
3.1A). These results show that following infection with a WT pneumococcal 
strain, BMMs release the pro-inflammatory cytokine IL-1β and that this is 
dependent on bacterial uptake and expression of the pneumococcal pore-
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forming toxin.  
To ascertain whether IL-1 family cytokines are expressed in vivo 
during pneumococcal colonization, mice were intranasally inoculated with the 
WT S. pneumoniae strain. Cytokine levels could not be detected because the 
airway surface fluid is highly diluted in lavages from the upper respiratory 
tract. Therefore, lysates of the respiratory epithelium were obtained and 
quantitative RT-PCR (qRT-PCR) preformed to assess Il1a (Fig. 3.2A) and Il1b 
(Fig. 3.2B) gene expression. We observed that upon colonization with S. 
pneumoniae (Spn) Il1b (Fig. 3.2B) was significantly up-regulated compared 
to mock colonized mice. A much smaller but significant increase in Il1a (Fig. 
3.2A) expression was observed. Inflammasome components, including pro-
IL-1β, are up-regulated upon TLR signaling and this ‘priming’ provides the 
first signal required for inflammasome activation (16, 38, 129). Previous 
studies of inflammasome activation and IL-1β release following 
pneumococcal infection in vitro have characterized TLR2 dependent IL-1β 
secretion (282). To determine the role of TLR2 in the up-regulation of Il1a 
and Il1b gene transcripts during pneumococcal colonization, we inoculated 
TLR2-deficient (Tlr2-/-) mice with WT Spn, obtained lysates of the epithelial 
tissue, and performed qRT-PCR to measure Il1a and Il1b transcription. We 
found that Tlr2-/- mice had no significant up-regulation of Il1a (Fig. 3.2C) or 
Il1b (Fig. 3.2D), demonstrating that the increased expression of both genes 
in vivo is dependent on TLR2.  
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Sensing of IL-1 cytokines is required for inflammation and macrophage 
driven bacterial clearance 
The role of IL-1 sensing in early events in pneumococcal colonization 
was investigated by inoculating wild type (WT) and type 1 IL-1 receptor 
deficient (Il1r1-/-) mice with S. pneumoniae and obtaining PBS lavages of the 
upper respiratory tract at 3 days post-infection. We assessed bacterial 
burden and host immune cell infiltrates by plating for colonizing pneumococci 
and flow cytometry, respectively. We observed no significant difference in 
bacterial numbers in the nasopharynx (Fig. 3.3A), however, there were 
significantly lower numbers of neutrophils in lavages from the Il1r1-/- mice 
compared to WT mice (Fig. 3.3B). Macrophage numbers were low, consistent 
with previous studies (60, 291), and there was no significant difference 
between the two groups (Fig. 3.3C). These results suggest that Il1r1-/- mice 
have a dampened early inflammatory response to S. pneumoniae 
colonization.  
To address the role of IL-1 sensing in subsequent clearance of 
colonization, WT and Il1r1-/- mice were inoculated with S. pneumoniae and 
bacterial counts and cellular infiltrates were quantified at 14 days post-
infection. We observed that WT mice had a significantly lower bacterial load 
compared to day 3 post-infection (Fig. 3.3A), indicating a partial clearance of 
pneumococcal colonization. In contrast, Il1r1-/- mice had no difference in 
bacterial numbers between days 3 and 14 post-colonization (Fig. 3.3A). 
Additionally, two weeks after inoculation there was a significantly higher 
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bacterial burden in the Il1r1-/- mice compared to WT (Fig. 3.3A). There were 
similar quantities of neutrophils present in the nasopharynx (Fig. 3.3D) of WT 
and Il1r1-/- mice. However, the numbers of macrophages, the effectors of 
pneumococcal clearance (291), were significantly decreased in the Il1r1-/- 
group (Fig. 3.3E). This attenuated clearance and delayed macrophage 
recruitment resembles previous findings in Tlr2-/- mice and WT mice 
colonized with a pneumolysin-deficient mutant (267, 291), both factors 
implicated in inflammasome activation. From these findings we conclude that 
sensing by the IL-1 receptor is required for increased macrophage presence 
in the nasopharynx and clearance of pneumococci.  
The contribution of IL-1β to clearance of pneumococci from the 
nasopharynx was assessed by administration of recombinant cytokine after 
colonization with a pneumolysin-deficient S. pneumoniae strain. This strain 
was used to minimize endogenous production of cytokine. Following the 
establishment of colonization, the mice were intranasally dosed with a low 
(100 ng) or high (200 ng) amount of IL-1β every other day. At 14 days post-
infection PBS lavages of the respiratory tract were obtained and bacterial 
quantity was measured. We observed a significant dose-dependent decrease 
in bacterial numbers when mice received intranasal IL-1β (Fig. 3.3F). This 
suggests that IL-1β is sufficient to promote clearance of pneumococcal 
colonization. 
 
Il1r1-/- mice have altered macrophage chemokine expression 
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Previous studies investigating clearance of pneumococcal colonization 
have characterized an essential role for the host C-C chemokine receptor 
CCR2 in macrophage recruitment and retention in the nasopharynx (60). 
CCR2 binds multiple ligands in the C-C motif chemokine family, that act as 
macrophage attractants (170). To assess the role of IL-1 sensing in 
macrophage recruitment to the nasopharynx we investigated the expression 
of several CCR2 ligands during pneumococcal colonization. WT and Il1r1-/- 
mice were inoculated with S. pneumoniae and at days 3 and 14 post-
colonization we obtained lysates of the upper respiratory tract and 
determined chemokine expression by qRT-PCR. We observed no significant 
difference between WT and Il1r1-/- mice in expression of any CCR2 ligand at 
day 3 post-inoculation (Fig. 3.4A). At day 14 post-infection, when clearance 
had initiated, Il1r1-/- mice had significantly lower expression of Ccl6 
compared to WT mice (Fig. 3.4B). These findings demonstrate that Il1r1-/- 
mice have an altered macrophage chemokine profile, which includes a 
reduction in CCL6 expression that correlates with lower macrophage 
presence and delayed clearance. 
 
Il1r1-/- mice do not have altered adaptive immunity to the pneumococcus 
Although there is a contribution of type-specific antibody to protection 
induced by either vaccination or prior exposure (55, 163), effective clearance 
of primary colonization requires Th17-dependent cellular immunity rather 
than humoral responses (157, 291). Il-1β is a known driver of Th17 
! 73!
responses (46), which contribute to macrophage recruitment during 
colonization (291). We investigated this potential role of IL-1 sensing in cell-
mediated immunity by comparing expression of Il17a in WT and Il1r1-/- 
colonized mice by qRT-PCR. We observed no significant difference in Il17a 
transcription between the WT and Il1r1-/- mice (Fig. 3.5A). To address a 
possible effect on humoral immunity, we measured the geometric mean titer 
(GMT) of whole anti-pneumococcal serum IgG from WT and Il1r1-/- colonized 
mice. Both groups had detectable antibody titers, though there was no 
significant difference in GMT (Fig. 3.5B). The development of adaptive 
immunity to the pneumococcus was interrogated using a secondary challenge 
model. WT and Il1r1-/- mice were colonized with S. pneumoniae and allowed 
to clear for a period of 8 weeks. The mice were then re-challenged with a 
marked isogenic strain that could be distinguished from the primary 
challenge strain and at day 4 post-colonization nasal lavages were obtained 
and bacterial quantity measured. Compared to the bacterial burden observed 
at day 3 during primary colonization, WT mice had significantly lower CFUs in 
the nasopharynx upon secondary challenge (Fig. 3.5C). Similarly, the Il1r1-/- 
mice also exhibited a significant drop in bacterial levels upon secondary 
colonization of an immune host (Fig. 3.5C).  Together these data show that 
signaling through the IL-1 receptor contributes to inflammation without 
impacting adaptive immune responses to pneumococcal colonization. 
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Discussion 
Host defense against S. pneumoniae requires the activity of 
professional phagocytes and previous studies have defined a critical role for 
macrophages in the clearance of colonization (291). This macrophage 
presence in the nasopharynx is driven by sensing of pneumococcal 
components that access the host cell cytosol through the action of the pore-
forming toxin pneumolysin (60, 151). Cytosolic access results in death of the 
phagocytes that clear the organism. However, this appears to result in pro-
inflammatory cytokine production, mediated by activation of the 
inflammasome, which further contributes to sustaining the inflammatory 
response against the colonizing pneumococci. 
Pneumococcal strains have been reported to vary in their ability to 
activate inflammasome signaling (282), however our observation that 
macrophages activate caspase-1 and secrete IL-1β following pneumococcal 
infection aligns with previous studies that have reported similar findings in 
other cell types with different pneumococcal strains (72, 133, 175). These 
investigations have demonstrated a pneumolysin-dependent activation of 
both the NLRP3 (133, 175) and AIM2 inflammasomes (72), which sense 
membrane perturbations and cytosolic DNA respectively. While recombinant 
pneumolysin alone, presumably acting at the plasma membrane, can activate 
the NLRP3 inflammasome (175), caspase-1 maturation and IL-1β secretion 
following infection with whole bacteria requires phagocytosis (72). This 
suggests that the virulence activity of pneumolysin, which triggers 
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inflammasome formation, occurs at the phagosome membrane.  
  The NLRP3 receptor and ASC signaling adaptor protein have both been 
implicated in defense against pneumococcal pneumonia (72, 175) and 
corneal infection (133). However, nasopharyngeal colonization is the most 
common pneumococcal-host interaction and until now the role of 
inflammasome derived innate immune signaling during carriage has not been 
addressed. While we have defined a critical role for sensing by the IL-1 
receptor during of S. pneumoniae colonization, the specific IL-1 receptor 
agonists that contribute to bacterial clearance remain to be defined. 
Nevertheless, IL-1β is highly expressed during colonization and is sufficient 
to reduce S. pneumoniae density. 
Our observation that sensing of IL-1 family cytokines contributes to 
inflammation in the nasopharynx following pneumococcal colonization 
complements previous reports that IL-1β and IL-1 receptor signaling is 
important for host defense against disease states caused by other mucosal 
pathogens, including Staphylococcus aureus (117) and group B 
Streptococcus (GBS) (27). Both of these organisms trigger IL-1β secretion 
through toxin-dependent activation of the inflammasome (97, 166), which 
drives neutrophil activation and pro-inflammatory cytokine production that 
controls infection (26, 189). The contribution of inflammasome signaling 
during natural carriage of these organisms remains unexplored. Unlike S. 
aureus or GBS, neutrophil responses are insufficient to clear S. pneumoniae 
during infection (291) and IL-1β appears to contribute to the macrophage 
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recruitment that promotes reduction in bacterial burden. The requirement for 
IL-1 sensing in macrophage recruitment during bacterial infection is less well 
understood. However, IL-1 sensing in the lung during fungal infection is 
known to enhance expression of both neutrophil and macrophage 
chemokines (39). Macrophage presence during pneumococcal colonization is 
dependent on host expression of CCR2, which binds multiple ligands. We 
observe that Il1r1-/- mice have diminished macrophage numbers in the 
nasopharynx two weeks after pneumococcal colonization, which correlates 
with significantly lower expression of CCL6. 
CCL6 is a C-C motif chemokine originally indentified in murine bone 
marrow (206). It acts as a macrophage chemoattractant (147) and is highly 
expressed in peripheral eosinophils and elicited macrophages (147, 285), as 
well as lung tissue (109, 132) and epithelial cells of the intestinal mucosa 
(145). In addition to its chemokine functions, CCL6 may have intrinsic 
antibacterial properties (145) and over expression of CCL6 in transgenic mice 
confers protection against bacterial sepsis (48). Multiple studies have 
observed that in contrast to CCL2, which is expressed early during 
inflammation, CCL6 induction occurs later and is sustained for several days 
to over a week (207, 285). These results, from a model of peritonitis, 
suggest that CCL2 acts in initial macrophage recruitment and that CCL6 
sustains macrophage presence. This raises the possibility that IL-1 cytokines, 
generated as a result of pro-inflammatory macrophage death during 
pneumococcal colonization, contribute to the chemokine production that 
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sustains macrophage presence throughout the course of bacterial clearance.  
Previous studies have defined an important role for the intracellular 
receptor Nod2 in innate immune defense against pneumococci (60). 
However, in these studies, a minimal clearance defect was observed in Nod2-
deficient mice, although mice lacking both Nod2 and TLR2 had a significantly 
higher bacterial burden at a time point when WT mice had no bacterial 
carriage. Combined with our observation that up-regulation of IL-1 cytokines 
is dependent on TLR2, this suggests that cytosolic access of pneumococcal 
components triggers two innate immune sensing pathways, both of which 
contribute to the orchestrated immune response that clears colonization. 
Activation of multiple sensing pathways may also be critical for controlling 
pneumococcal disease. Patients deficient in MYD88 or IRAK-4, adaptor 
proteins for both TLRs and the IL-1 receptor, are acutely susceptible to 
recurrent pneumococcal sepsis (21, 50, 146, 212, 213). However, 
polymorphisms in TLRs alone do not correlate with significant increases in S. 
pneumoniae disease (182), suggesting that sensing by both TLRs and the IL-
1 receptor may be critical for host defense. 
 Although pneumolysin-mediated cytosolic access triggers innate 
immune responses that eventually clear S. pneumoniae, this may still be to 
the benefit of the bacterium. Cytosolic access results in the death of the 
phagocytes that clear the organism and generates IL-1 family cytokines that 
drive inflammation, an important factor in both bacterial growth (247) and 
transmission (244). Sensing of IL-1 cytokines, however, does not appear to 
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contribute to the development of an adaptive immune response, suggesting 
that toxin expression and cytosolic access drives IL-1 cytokine-mediated 
inflammation that benefits the organism without inducing further immunity 
that is detrimental to its persistence. 
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Figure 3.1. Pneumococcal infection results in IL-1β release in vitro 
(A and B) Bone marrow-derived macrophages (BMMs) were infected with wild 
type (WT) or pneumolysin-deficient (ply-) S. pneumoniae strains or left 
uninfected (Un). Where indicated, BMMs were treated with 20µM cytochalasin 
D (CytD) to block phagocytosis. Supernatants were collected at 24 hours 
post infection.  
(A) Western blot of supernatants for the presence of caspase-1 (Casp-1) and 
interleukin-1 beta (IL-1β). BMMs primed with 0.5 µg/mL LPS and stimulated 
with ATP were used as a positive control (PC). Representative images shown.  
(B) Amounts of IL-1β in supernatants were quantified by ELISA. Results are 
from 2 independent experiments, error bars represent ± SEM, One-way 
ANOVA with Newman-Keuls post test, ***P < 0.001. 
Un WT ply- PC 
-CytD 
Un WT ply- 
+CytD 
Casp-1 p10 
Pro-casp-1 
Pro-IL-1β 
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A B 
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Figure 3.2. Expression of IL-1 cytokines is up-regulated during S. 
pneumoniae colonization and is dependent on TLR2. 
(A-D) Wild type (black bars) or TLR2-deficient (Tlr2-/-, white bars) mice were 
intranasally inoculated with 107 CFU of S. pneumoniae (Spn). At 14 days 
post-colonization the upper respiratory tracts were lavaged with RLT RNA 
lysis buffer. Gene expression relative to PBS (Mock) inoculated mice was 
measured by quantitative RT-PCR for Il1a (A and C) and Il1b (B and D). 
Results are from at least 2 independent experiments, n > 10 mice, error bars 
represent ± SEM, Mann-Whitney U test, *P < 0.05, ***P < 0.001, ns, not 
significant. 
 
A" B"
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Figure 3.3. Sensing of IL-1 family cytokines is important for bacterial 
clearance and macrophage recruitment. 
(A-E) Wild type (WT, black) or IL-1 receptor-deficient (Il1r1-/-, grey) mice 
were intranasally inoculated with 107 CFU of S. pneumoniae and at the time-
points indicated PBS lavages of the upper respiratory tract were obtained.  
(A) Bacterial numbers of colonizing pneumococci were quantified by plating 
of nasal lavages. Dashed line indicates limit of detection. Results are from 2 
to 4 independent experiments, n ≥ 10 mice per group, error bars represent 
± SEM, Kruskal-Wallis with Dunn’s post-test, **P < 0.01, ns, not significant.  
(B-E) Cellular infiltrates in the nasal lavages of 5 mice were measured by 
flow cytometry. Quantification of neutrophils  (Ly6G+, CD11b+) and 
monocytes/macrophages (F4/80+, CD11b-) after 3 (B and C) and 14 (D and 
E) days of colonization are shown. Results are from 4 independent 
experiments, error bars represent ± SEM, Student’s t-test or Mann-Whitney 
U test as appropriate, *P < 0.05, ns, not significant.  
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Figure 3.3 Continued. 
(F) WT mice were inoculated with 107 CFU of a pneumolysin-deficient S. 
pneumoniae strain and intranasally administered 100 or 200 ng of 
recombinant IL-1β (white circles) or vehicle control (PBS, black circles) every 
other day for 14 days. Nasal lavages were obtained and numbers of 
pneumococci were measured by plating serial dilutions. Dashed line indicates 
limit of detection. Results are from 2 experiments, n ≥ 4 mice per group, 
error bars represent ± SEM, Kruskal-Wallis with Dunn’s post-test, *P < 0.05.
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Figure 3.4. Il1r1-/- mice have altered C-C chemokine profiles during 
S. pneumoniae colonization. 
(A and B) Wild type (WT, black bars) or IL-1 receptor-deficient (Il1r1-/-, grey 
bars) mice were inoculated with 107 CFU of S. pneumoniae. At 3 (A) and 14 
(B) days post-colonization RLT RNA lysis buffer lavages of the upper 
respiratory tract were obtained and gene expression of Ccl2, Ccl6, Ccl7, and 
Ccl8 was measured by quantitative RT-PCR. Values are relative to PBS 
(Mock) inoculated mice. Results are from 2 to 4 independent experiments, n 
≥ 9 mice, error bars represent ± SEM, Mann-Whitney U test, *P < 0.05, **P 
< 0.01, ns, not significant. 
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Figure 3.5. Sensing of IL-1 does not alter adaptive immunity to the 
pneumococcus. 
(A and B) Wild type (WT, black bars) or IL-1 receptor-deficient (Il1r1-/-, grey 
bars) mice were intranasally colonized with S. pneumoniae (Spn) for 14 
days.  
(A) RLT RNA lysis buffer lavages of the respiratory tract were obtained and 
expression of Il17a was measured by quantitative RT-PCR. Values are 
reported as fold-change relative to PBS (Mock) inoculated mice. Student’s t-
test, ns, not significant. 
(B) Total anti-pneumococcal serum IgG levels were measured by ELISA. 
Values are expressed as geometric mean titer (GMT), Kruskal-Wallis with 
Dunn’s post-test, ns, not significant. 
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Figure 3.5 Continued. 
(C) WT (black circles) or Il1r1-/- (grey circles) mice were inoculated with 107 
CFU of S. pneumoniae. For primary (1°) colonization, mice were sacrificed at 
day 3 post-colonization, PBS nasal lavages obtained, and bacterial density 
measured by plating. For secondary (2°) colonization, mice were allowed 8 
weeks to clear the pneumococci and then rechallenged with an isogenic S. 
pneumoniae strain distinguishable by antibiotic resistance. Nasal lavages 
were obtained at day 4 post-secondary colonization and bacterial density was 
quantified by plating. Dashed line indicates limit of detection. Results are 
from 2 to 5 independent experiments, n ≥ 10 mice, error bars represent ± 
SEM, Kruskal-Wallis with Dunn’s post-test, **P < 0.01, ***P < 0.001. 
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CHAPTER IV 
 
 
Materials and Methods 
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Bacterial Strains and Mutants 
S. pneumoniae strains were grown overnight at 37°C on trypic soy (TS) agar 
plates containing 5% sheep blood (BD) and the following day, liquid cultures 
were inoculated into broth TS and incubated in a nonshaking water bath at 
37°C to mid-log phase (OD≈0.5). The wild type 23F strain was originally 
isolated from an experimental human carriage study (173). Mutations in 
pgdA and adr (59) were introduced into previously described S. pneumoniae 
strains that were either deficient in or corrected for pneumolysin expression 
(60, 171) by transformation with chromosomal DNA, followed by selection for 
kanamycin (500 µg/mL) and spectinomycin (200 µg/mL) resistance, 
respectively. Sensitivity to lysozyme was phenotypically confirmed by in vitro 
bacterial lysis as previously described (59). The plyTL→AA mutation, containing 
previously characterized alanine mutations at the threonine and leucine 
residues responsible for binding cholesterol (73),  was constructed using 
overlap extension PCR with primer pairs to introduce the two alanine 
mutations (Fwd 5’–TGG GGA ACA GCT GCC TAT CCT CAG GTA GAG GAT-3’ 
and Rev 5’-ATC CTC TAC CTG AGG ATA GGC AGC TGT TCC CCA-3’) and 
primers flanking the pneumolysin gene (Fwd 5’-AAA AAA GAA GCC GAT AAG 
GAA AAG ATG AGC G-3’ and Rev 5’-GAA AGT TTC AGC CAA GTT TGA CAA 
AGT CAG CTC-3’). The amplified construct was introduced into a 23F 
pneumococcal strain containing a Janus Cassette (253) in place of the 
pneumolysin gene by transformation and homologous recombination. 
Transformants were selected for streptomycin resistance (200 µg/mL) and 
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sensitivity to kanamycin (200 µg/mL) was confirmed by patching. 
Pneumococci were pelleted by centrifugation at 14,000 rpm and resuspended 
in phosphate buffered saline (PBS). 
 
 
Hemolysis Assay 
As previously described (223), pellets of wild type (WT), pneumolysin- 
deficient (ply-), pneumolysin toxoid (plyTL→AA), or corrected (ply+) S. 
pneumoniae cultures were lysed in 400 µL lysis buffer (0.01% sodium 
dodecyl sulfate, 0.1% sodium deoxycholate, and 0.015M sodium citrate) and 
incubated at 37°C for 30 min. Lysates were then transferred to a 96-well V-
bottom plate and serially diluted three fold in DTT buffer (10 mM 
dithiothreitol, 0.1% bovine serum albumin in phosphate buffered saline). 2% 
horse red blood cells were added to each well and incubated at 37°C for 30 
min. Plates were centrifuged for 10 min at 3000 rpm to pellet unlysed cells 
and imaged. 
 
 
Cell Culture 
Bone-marrow cells harvested from the femurs and tibiae of C57BL/6, FVB/N, 
LysM-/-, and Tlr4-/- mice were differentiated into macrophages by culturing in 
Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 30% L929 
supernatant, and 20% FBS at 37°C with 5% CO2 for 7-9 days. One day prior 
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to infection, macrophages were replated in DMEM supplemented with 15% 
L929 enriched supernatant and 10% FBS. All animal experiments were 
conducted according to the guidelines outlined by National Science 
Foundation Animal Welfare Requirements and the Public Health Service Policy 
on the Humane Care and Use of Laboratory Animals. The protocol was 
approved by the Institutional Animal Care and Use Committee, University of 
Pennsylvania Animal Welfare Assurance Number A3079-01, protocol number 
803231. 
 
 
Immunofluorescence Staining and Confocal Microscopy 
BMMs were seeded on to poly-L lysine-coated coverslips (BD) in a 24-well 
plate at a density of 2.5x105 cells/slip and the following day, were incubated 
with non-opsonized pgdA-/adr- pneumococci at MOI=10 for 2.5 hours, 
washed with PBS, and fixed in 3% paraformaldehyde. Cells were quenched 
with 50 mM NH4Cl and permeabilized with PGS (0.01% saponin, 0.25% 
gelatin, 0.02% sodium azide, in PBS). To detect pneumococcal capsular 
polysaccharide, the cells were incubated with type 23F rabbit serum (Statens 
Serum Institut) at a dilution of 1:5000 and detected with an anti-rabbit-Cy3 
secondary antibody (Jackson ImmunoResearch) at a dilution of 1:600 in PGS. 
Phagosome membranes were labeled with a rat anti-Lamp-1 antibody 
(eBioscience) at a dilution of 1:500 in PGS and primary antibody was 
detected with an anti-rat Cy2-conjugated secondary antibody (Jackson 
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ImmunoResearch) at a dilution of 1:600 in PGS. Nuclei were stained with 0.5 
ug/mL DAPI for 3 min. Slides were imaged on a Nikon Eclipse Ti-U spinning 
disk confocal microscope at the Molecular Pathology and Imaging Core at the 
University of Pennsylvania.  
 
 
Electron Microscopy 
Macrophage samples were high pressure frozen in an Abra HPM-010 and 
freeze substituted in 99% acetone, 0.1% uranyl acetate, 1% dH2O in a Leica 
AFSII. Freeze substitution was performed at -90°C for 72 hours and then 
ramped to -50°C over 24 hours where cells were placed in four hour graded 
steps of 25%, 50%, 75%, 100% HM-20 in acetone. HM-20 was polymerized 
with 360 nm light for 48 hrs at -50°C and an additional 24 hours at room 
temperature.  Polymerized blocks trimmed to regions of interest were cut at 
60-80 nm thickness and immunologically probed with IgG purified type 23F 
rabbit serum. Protein A conjugated to 15 nm colloidal gold was used to 
secondarily detect the presence of antibody-antigen complexes. Imaging was 
performed on a JEOL 1010 TEM operating at 80 KeV. 
 
 
Cellular Fractionation 
BMMs were seeded in a 6-well, non-tissue culture-treated plate at a density 
of 1x106 cells/well. The following day, the cells were infected with non-
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opsonized pneumococcal strains at MOI=50 and spun for 5 min at 3000 rpm. 
Where indicated, the BMMs were incubated with 20 µM cytochalasin D 
(Sigma), 30 nM bafilomycin A, (Sigma) or 10 µM SB203580 (Cell Signaling) 
at 37°C for 1 hour prior to infection. Following infection, the cells were 
incubated on ice for 1 hour, washed five times with PBS, and incubated for 
an additional 2 hours at 37°C. BMMs were washed three times with PBS, 
lifted with PBS containing 2 mM EDTA and permeabilized in 20 µM digitonin 
(Sigma) to lyse the plasma membrane to generate cytosol fractions, or 0.1% 
saponin (Fluka) to lyse all membranes to generate whole cell fractions.  Cells 
were spun at 15,000 g for 10 min and the resulting supernatants were 
ultracentrifuged at 4°C for 1 hour at 355,000 g. Supernatants were 
lyophilized and resuspended in dH2O. 
 
 
Gentamicin Protection Assay 
BMMs were seeded in a 12-well plate at a density of 4x105 cells/well and, the 
following day, infected with pneumococcal strains at MOI=50 and spun for 5 
min at 3000 rpm. The BMMs were incubated on ice for 1 hour, then washed 
three times with PBS, and incubated at 37°C for 15 min for bacterial uptake. 
300 µg/ml gentamicin was then added to kill remaining extracellular bacteria. 
At the time points indicated, the cells were lysed with dH2O and serially 
diluted in PBS. Dilutions were plated on TS agar plates and incubated 
overnight at 37°C/5% CO2. 
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Cytotoxicity Assay 
BMMs were seeded in a 48-well plate at a density of 2.5x105 cells/well and 
cultured overnight at 37°C. The following day the cells were primed with 400 
ng/mL Pam3CSK4 for 4 hours and then infected with S. pneumoniae at 
MOI=10. At 2 hours post-infection the cell culture medium was replaced with 
DMEM containing 300 µg/mL gentamicin. Supernatnants from infected 
macrophages were collected at 24 hours post-infection. Lactate 
dehydrogenase release was quantified using the Cytotoxicity Detection Kit 
Plus (Roche) per the instructions of the manufacturer.  
 
 
ELISA for IL-1β 
Supernatants harvested at 24 hours post-infection were assayed for the 
presence of IL-1β using the ELISA MAX Mouse IL-1β Kit (BioLegend) per the 
instructions of the manufacturer.  
 
 
Western Blotting 
Supernatants from BMMs infected with pneumococci were harvested at 24 
hours post-infection, separated on a 10% Tris-SDS gel (BioRad) and detected 
by primary antibody incubation for Caspase-1 (Santa Cruz) at a dilution of 
1:200 and IL-1 beta (AbCam) at a dlution of 1:2000. Sub-cellular fractions 
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from BMMs were validated by running resuspended supernatants on a 10% 
Tris-SDS gel (BioRad). Monoclonal anti-Lactate dehydrogenase and 
polyclonal anti-Cathepsin B antibodies (AbCam) were used for primary 
detection. Lysates from S. pneumoniae strains expressing pneumolysin 
mutations were separated on a 10% Tris-SDS gel and detected using a 
mouse monoclonal anti-pneumolysin primary antibody (Leica) and previously 
described (57) anti-pneumococcal surface protein A (PspA) mouse serum. 
Rabbit horseradish peroxidase (HRP) conjugated (GE Healthcare) and mouse 
HRP conjugated (GE Healthcare) antibodies were used for detection of the 
primary antibodies.  
 
 
ELISA for Capsular Polysaccharide 
Sub-cellular fractions of infected BMMs were assayed for pneumococcal CPS 
by capture ELISA. Immulon 2HB plates (Thermo Scientific) were coated with 
type 23F rabbit serum at a dilution of 1:5000 and incubated overnight at 
room temperature (RT). The plate was incubated with serial dilutions of 
samples or a type 23F CPS standard (ATCC) for 2 hours at RT. Samples and 
standards were detected with a monoclonal anti-23F CPS antibody at a 1:300 
dilution for 2 hours at RT. Monoclonal antibody was detected with a goat 
anti-mouse alkaline phosphotase antibody (Sigma) at a 1:10000 dilution for 
2 hours at RT. The plate was developed with phosphatase substrate (Sigma) 
for 30 min and read at OD=415nm.  
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Murine Model of S. pneumoniae Nasopharyngeal Colonization 
C57BL/6 (WT) and Tlr2-/- mice were obtained from The Jackson Laboratory. 
Il1r1-/- mice (89) were a generous gift from Sunny Shin (University of 
Pennsylvania). 107 colony forming units (CFU) of S. pneumoniae in 10 µL PBS 
were inoculated into the nares of unanesthetized mice. Inocula were serially 
diluted in PBS and grown overnight on TS agar plates to verify dose. At the 
time points indicated in the figures, the mice were sacrificed, the trachea 
cannulated, and lavaged with 200 µL PBS through the nares. The resulting 
lavage fluid was plated in serial dilutions on TS agar plates, grown overnight 
at 37°C/5% CO2, and the following day CFU counted. For intranasal 
administration of cytokine, WT mice colonized with a pneumolysin-deficient 
S. pneumoniae strain (222) received 100 or 200 ng of recombinant IL-1β 
(eBioscience) resuspended in 10 µL PBS or 10 µL PBS alone as a vehicle 
control every other day for 14 days. For secondary challenge experiments, 
mice of the indicated genotype were colonized with WT S. pneumoniae and 
allowed 8 weeks to clear colonization. They were then re-colonized with an 
isogenic strain containing a single point mutation that confers resistance to 
streptomycin and has no colonization defect (63, 253).  
  
 
Quantitative RT-PCR 
Following lavage with PBS, sacrificed mice were lavaged with 600 µL RLT 
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RNA Lysis buffer (QIAGEN) containing 10% 2-mercaptoethanol. Samples 
were stored at -80°C until RNA was isolated using a QIAshredder Kit 
(QIAGEN) followed by an RNeasy Mini Kit (QIAGEN) per the manufacturers 
protocol. Complementary DNA (cDNA) was reverse transcribed using a high-
capacity cDNA kit (Applied Biosystems). 10 ng cDNA was used as a template 
in each reaction with 0.5 µM forward and reverse primers and Power SYBR 
Green (Applied Biosystems) per the manufacturers protocol. Reactions were 
amplified with the StepOnePlus Real-Time PCR system (Applied Biosystems) 
and comparisons were calculated using the ΔΔCT method. The following 
primers were used for amplification: GAPDH-F: 5’-AGG TCG GTG TGA ACG 
GAT TTG-3’; GAPDH-R: 5’-TGT AGA CCA TGT AGT TGA GGT CA-3’; IL-1A-F: 
5’-GCA CCT TAC ACC TAC CAG AGT-3’; IL-1A-R: 5’-TGC AGG TCA TTT AAC 
CAA GTG G-3’; IL-1B-F: 5’-GCA ACT GTT CCT GAA CTC AAC T-3’; IL-1B-R: 
5’-ATC TTT TGG GGT CCG TCA ACT-3’; CCL2-F: 5’-AGC TCT CTC TTC CTC 
CAC CAC-3’; CCL2-R: 5’-CGT TAA CTG CAT CTG GCT GA-3’; CCL6-F: 5’-ATG 
AGA AAC TCC AAG ACT GCC-3’; CCL6-R: 5’-TTA TTG GAG GGT TAT AGC GAC 
G-3’; CCL7-F: 5’-GCT GCT TTC AGC ATC CAA GTG-3’; CCL7-R: 5’-CCA GGG 
ACA CCG ACT ACT G-3’; CCL8-F: 5’-TCT ACG CAG TGC TTC TTT GCC-3’; 
CCL8-R: 5’-AAG GGG GAT CTT CAG CTT TAG TA-3’; IL-17A-F: 5’-TTT AAC 
TCC CTT GGC GCA AAA-3’; IL-17A-R: 5’-CTT TCC CTC CGC ATT GAC AC-3’ 
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Flow Cytometry 
PBS lavages from 5 mice were pooled per group, pelleted at 1500 rpm for 10 
min and resuspendend in PBS containing 1% bovine serum albumin (BSA). 
Samples were first blocked for 10 min in 1% BSA (Sigma-Aldrich) and then 
blocked again with a rat anti-mouse FcγIII/II receptor antibody (BD). Cells 
were stained for 30 min at 4°C with a cocktail of the following rat anti-mouse 
antibodies: CD4-FITC (BD), Ly6G-PE (BioLegend), Cd11b-PerCP cy5.5 
(BioLegend), and F4/80-APC (eBioscience).  
 
 
Quantification of Anti-pneumococcal Serum IgG 
The wild type 23F strain used for colonization was grown to mid-log phase in 
TS, pelleted, and resuspended in coating buffer (0.015 M Na2CO3, 0.035 M 
NaHCO3, pH 9.6) to OD620=0.1. Immulon 2HB 96-well plates (Thermo) were 
coated with pneumococci by incubating 100 µL per well of resuspension 
overnight at 4°C. Plates were blocked for 1 hr at 37°C in 1% BSA in PBS and 
washed with PBS containing 0.05% Brij-35 (Fisher). Serum samples were 
serially diluted 2-fold and incubated overnight at 4°C.  The plates were 
washed with 0.05% Brij-35 in PBS and pneumococcal-specific antibodies 
were detected by incubation with a goat anti-mouse IgG alkaline 
phosphatase conjugated antibody for 1.5 hrs at room temperature. Plates 
were developed for 1 hr at 37°C using phosphatase subtrate (Sigma) and 
read at 415 nm.  Geometric mean titers were calculated based on the sample 
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dilution where absorbance = 0.1. 
 !
! 100!
!
CHAPTER V 
 
 
Summary and Discussion 
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Cytosolic access is dependent on phagocytosis and lysozyme  
Our studies define several host factors that are required for S. 
pneumoniae killing and subsequent cytosolic access of pneumococcal 
components. Previous work from our lab indicates that this phenomenon 
occurs in vivo (60) however, our studies investigated cytosolic access in an in 
vitro cell culture system. This was necessary because macrophages in the 
upper respiratory tract are of low abundance and remain poorly 
characterized. Working in a cell culture system however, allowed us to use 
high enough cell numbers that we could quantify cytosolic contents, as well 
as employ pharmacologic agents and genetic knock-outs to better dissect the 
mechanism of cytosolic access of pneumococcal components.  Phagocytosis is 
the first step in this host-pathogen interaction and inhibition of bacterial 
uptake prevents pneumococcal components from accessing the cytosol. The 
scavenger receptor MARCO promotes both bacterial uptake and Nod2-
dependent sensing of pneumococci in vitro and MARCO-deficient mice have 
impaired clearance of S. pneumoniae colonization (67). This indicates that 
phagocytosis of pneumococci by macrophages in non-immune hosts occurs 
through bacterial binding of this scavenger receptor, which leads to cytosolic 
access that triggers Nod2-dependent innate immune signaling cascades.  
Once inside the phagosome, pneumococci are subject to a battery of 
host defenses, including acidification, proteases, and reactive oxygen species 
from the respiratory burst. Previous studies have determined that nitric oxide 
contributes to pneumococcal killing by macrophages (167) and our findings 
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further characterize how the host cell achieves destruction of the 
pneumococcus. Our data show that host expression of the muramidase 
lysozyme is required for killing of S. pneumoniae (Fig. 2.2E) and that while 
cell wall modifications, which confer bacterial resistance to lysozyme on the 
mucosal surface (59), can delay pneumococcal killing by macrophages (Fig. 
2.2D), interaction with these professional phagocytes is still fatal for the 
pneumococcus. We further observe that access to the cytosol is independent 
of phagosome acidification (Fig. 2.5D). This finding is consistent with 
lysozyme-mediated degradation and killing, as this muramidase is 
enzymatically active at neutral pH (60).  
TLR4 has been reported to directly sense the pneumococcal pore-
forming toxin pneumolysin in vitro, although the requirement for TLR4 
signaling in protection from pneumococcal colonization and invasive disease 
remains a subject of debate (19, 65, 162). Our observation that TLR4 is not 
required for cytosolic access (Fig. 2.5B) is consistent with other studies 
investigating intracellular signaling pathways that are activated by 
pneumococcal infection. Pneumolysin triggers NLRP3-dependent 
inflammasome activation independently of TLR4 (175), and cytosolic access 
of pneumococcal DNA activates type I interferon signaling without 
contribution from TLR4 (208). Given that TLR4 signaling may defend against 
S. pneumoniae colonization (162), it remains possible that TLR4 is required 
for host defense against pneumolysin activity in epithelial cells rather than in 
professional phagocytes. 
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Cytosolic access requires pneumolysin 
In these studies, we define a critical role for the pneumococcal pore-
forming toxin pneumolysin in mediating transit of bacterial components to 
the cytosol of macrophages. We show that a pneumolysin-deficient 
pneumococcal strain has significantly impaired cytosolic access (Fig. 2.4B) 
and furthermore, the ability of pneumococcal components to access the 
cytosol requires pneumolysin binding of cholesterol in host membranes (Fig. 
2.4B). We were unable to ascertain whether pore-formation is specifically 
required for cytosolic access because a pneumococcal strain expressing a 
pneumolysin pore-forming mutant had an intermediate phenotype in our 
fractionation assay (data not shown). Pore-formation by pneumolysin is 
usually characterized by a hemolysis assay that measures the ability of the 
toxin to lyse horse red blood cells. While the pore-formation mutant is almost 
completely attenuated in this assay (144, 223, 239), we are unable to say 
whether there is still residual toxin activity in the context of pneumococcal 
degradation by professional phagocytes. 
Our finding that cytosolic access requires both expression of the 
pneumolysin toxin and its ability to bind host membranes provides further 
insight into how a host discriminates between commensal and potentially 
pathogenic microbes. Pneumolysin can facilitate transit of peptidoglycan to 
the cytosol of epithelial cells during co-infection with other bacterial species 
(222) and other members of the CDC toxin family are well known to 
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translocate effector proteins (160) or provide cytosolic access to live 
microbes (17, 216) as part of an organisms’ survival. In contrast, the action 
of pneumolysin on the host cell coincides with bacterial lysis and does not 
directly benefit the bacterium that releases the toxin. Recent work has 
characterized intracellular innate immune detection of other extracellular 
pathogens that is dependent on expression of their CDC toxins (97), 
suggesting that toxin-mediated escape of degraded bacterial fragments from 
the phagosome likely occurs for other microbes.  
 Additional mechanisms of cytosolic access of bacterial components 
have been described. A pneumococcal strain expressing a pneumolysin pore-
forming mutant causes lysosome destabilization at late time points (24 hours 
post-infection) (25), though exactly how this occurs is unresolved. Studies 
investigating the transit of MDP, the minimal Nod2 ligand (88), to the host 
cell cytosol have shown a critical role for the peptide transporters SLC15A3 
and SLC15A4 (196). Unlike previous reports linking the peptide transporters 
PEPT1 and PEPT2 to the transit of MDP to the cytosol (254, 269), this study 
further demonstrates the presence of these transporters and Nod2 on the 
phagosome membrane during bacterial infection (196). The possible 
contributions of SLC15A3 and SLC15A4 to cytosolic access of pathogens that 
express pore-forming toxins or do not survive in the phagosome provides an 
opportunity for future investigation, which could reveal that more than one 
route to the cytosol exists for the bacterial ligands that activate innate 
immune sensors. 
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Cytosolic access results in pro-inflammatory cell death and drives 
clearance of colonization 
Our observation that inhibition of p38 MAPK increases cytosolic access 
of pneumococcal components (Fig. 2.6B) shows that the host cell is able to 
sense and defend against the action of pneumolysin. P38 MAPK 
phosphorylation occurs rapidly in macrophages following incubation with 
pneumococci (58), suggesting that this sensing occurs at the plasma 
membrane, while the sequelae of p38 MAPK activation limits transit of 
bacterial products across the phagosome membrane. Although the host cell 
mounts this defense, accessing the cytosolic compartment results in death of 
the host cell. Our data demonstrate that this cytotoxicity is dependent on 
both bacterial uptake and expression of pneumolysin (Fig. 2.7). This 
‘mutually assured destruction’ – death of both the pneumococcus and the 
macrophage – may be a strategy by the bacterium to counteract the host 
cells responsible for its clearance.  
In these studies, we also show that host cell death results in IL-1β 
release in vitro and similar to cell death, is dependent on phagocytosis and 
bacterial expression of pneumolysin (Fig. 3.1B). This observation 
complements results in the literature reporting inflammasome activation and 
IL-1β release with a different pneumococcal strain in a variety of cell types 
(72, 133, 175). While we were unable to measure levels of mature cytokine 
in vivo, Il1r1-/- mice have delayed clearance of colonization (Fig. 3.3A), which 
correlates with lower numbers of macrophages in the nasopharynx (Fig. 
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3.3E), suggesting that sensing of IL-1 cytokines that results from cytosolic 
access contribute to bacterial clearance. However, our results demonstrate 
that expression of Il1a and Il1b increases upon colonization in a manner that 
is dependent on TLR signaling (Fig. 3.2), a finding that is consistent with 
cellular priming for inflammasome activation.  
Previous work from our lab defined a critical role for the intracellular 
host receptor Nod2 in clearance of pneumococcal colonization (60). 
Interestingly, these studies found that clearance of colonization was most 
significantly impaired in mice deficient in both Nod2 and TLR2, suggesting 
redundancy between these two pattern recognition receptors. Our studies 
define an additional intracellular innate immune pathway that is dependent 
on TLR stimulation, which is activated by S. pneumoniae and contributes to 
bacterial clearance from the host. It is therefore possible that both Nod2 
sensing and IL-1 cytokines contribute to clearance of pneumococci from the 
nasopharynx and that cytosolic access is the unifying event that triggers both 
of these host sensing mechanisms. 
Activating multiple innate immune pathways may also have significant 
contributions to host protection from pneumococcal disease. Children with 
deficiencies in either MYD88 or IRAK-4, molecules that are downstream of 
TLRs and the IL-1 receptor, experience recurrent pneumococcal disease (21, 
146, 213) that cannot be attributed to loss of TLR function alone (182). This 
implies that sensing of IL-1 cytokines, in addition to TLR activation, may 
have a critical role in defense against S. pneumoniae. 
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Why the pneumococcus would make a toxin that activates innate 
immune signaling that drives the host to clear it from its niche is a logical 
question resulting from these studies. Our observation that IL-1 sensing 
promotes inflammation in the nasopharynx without further contributing to 
the development of adaptive immune responses may provide some answers. 
The host inflammatory response to pneumococcal colonization promotes both 
bacterial growth (247) and transmission (244); therefore, production of IL-1 
cytokines during colonization may contribute to inflammation that promotes 
the pneumococcus’ lifestyle without impacting its ability to re-colonize the 
same host at a later time. 
 
 
Model of cytosolic access of pneumococcal components 
Based on our studies interrogating the mechanism by which 
pneumococcal components access the host cell cytosol, we propose a model 
of cytosolic access with critical roles for bacterial degradation by lysozyme 
and the function of the pore-forming toxin pneumolysin (Fig. 4.1). The 
presence of bacterial products in the cytosol is dependent on phagocytosis, 
indicating that bacterial uptake initiates this host-pathogen interaction. 
Killing of S. pneumoniae occurs rapidly following phagocytosis and 
pneumococcal degradation is delayed by bacterial modifications that confer 
resistance to lysozyme or in macrophages that are lysozyme-deficient. These 
findings demonstrate that lysozyme significantly contributes to bacterial 
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killing by macrophages. A lysozyme sensitive pneumococcal strain has 
increased amounts of bacterial components in the host cell cytosol, indicating 
that lysozyme degradation is also important for generating bacterial 
fragments that transit to the cytosol. Lysis of the bacterial cell causes the 
release of the pore-forming toxin pneumolysin, which is required for 
pneumococcal components to access the cytosol. Additionally, the ability of 
the toxin to bind cholesterol in the host membrane is necessary for cytosolic 
access to occur, demonstrating a critical role for toxin function in this 
phenomenon. The host is able to detect and limit toxin activity through p38 
MAPK activation, though ultimately these defenses are insufficient and the 
macrophage undergoes a pro-inflammatory cell death. Death of the 
macrophage results in the release of IL-1β and sensing of IL-1 family 
cytokines is required for successful macrophage recruitment and clearance of 
colonization (Fig. 4.2). The mechanism by which IL-1 cytokines promote 
macrophage-driven bacterial clearance is unknown, but provides an avenue 
of future inquiry. 
 
 
Future Directions 
The role of p38 MAPK activation in vivo 
 Our finding that p38 MAPK sensing of pneumolysin limits cytosolic 
access further contributes to the body of evidence that this signaling pathway 
is critical for defense against pore-forming toxins (116, 118, 223). Exactly 
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how p38 MAPK activation achieves this defense of the host cell is unclear and 
could be the subject of future investigation. Furthermore, the significance of 
p38 MAPK activation during pneumococcal colonization in vivo remains to be 
addressed. Studies of pneumococcal pneumonia have shown that p38 MAPK 
activation is critical for controlling bacterial burden (266), suggesting an 
important role for this signaling cascade in bacterial clearance at the mucosal 
surface and also demonstrating that inhibition of p38 MAPK can be achieved 
in vivo. However, the contribution of pneumolysin to p38 MAPK activation 
was not addressed in this study. In addition to pore-forming toxins, TLRs can 
activate P38 MAPK signaling and the contribution of pneumolysin or other 
pathogen associated molecular patterns in p38 MAPK-mediated defense 
during pneumococcal disease or colonization is still an open question. 
 
Determine the contributions of IL-1α and IL-1β to clearance of colonization 
Our findings define a critical role for sensing by the IL-1 receptor in 
detection and clearance of pneumococcal colonization, although we have not 
demonstrated which IL-1 receptor agonists are responsible for this 
phenotype. The type 1 IL-1 receptor is activated by binding of both IL-1α and 
IL-1β (84). While we show that IL-1β expression is highly induced during 
colonization (Fig. 3.2B) and administration of recombinant IL-1β is sufficient 
to promote a reduction in bacterial carriage (Fig. 3.3F), we have not 
excluded a potential contribution of IL-1α in the host immune response to 
pneumococcal colonization. Attempts to neutralize IL-1α and IL-β in 
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colonized mice by intraperitoneal injection of monoclonal antibodies at 
concentrations that are effective on the mucosal surface (42) did not 
significantly alter clearance of colonization at 14 days post-infection (data not 
shown). Nasal lavages are highly diluted and we could not detect cytokines in 
samples from the upper respiratory tract; therefore, we were unable to 
confirm cytokine depletion upon treatment with the neutralizing antibodies.  
To specifically address which IL-1 receptor ligands contribute to 
bacterial clearance from the nasopharynx, we could examine the dynamics of 
colonization in IL-1α or IL-1β-deficient mice (112, 113, 128). Following 
inoculation of these mice with S. pneumoniae, we would be able to assess 
bacterial burden and immune cell infiltrate over time and determine whether 
the absence of IL-1α or IL-1β alone phenocopies our findings from Il1r1-/- 
mice. We could also generate mice that lack both IL-1α and IL-1β to 
determine if these cytokines have redundant or synergistic contributions to 
clearance of colonization. These experiments would clarify the individual 
contributions of both IL-1α and IL-1β to the host immune response to S. 
pneumoniae colonization. 
 
Characterize the role of CCL6 in S. pneumoniae colonization 
Our observation that Il1r1-/- mice have lower expression of the 
macrophage chemokine CLL6 than WT mice during colonization gives rise to 
several avenues of further inquiry. Neutralization of CCL6 with depleting 
antibodies in colonized WT mice could show whether CCL6 is necessary for 
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clearance of pneumococci. This experiment, however, may have similar 
technical challenges in verifying depletion as the IL-1α and IL-1β depletion 
experiments we have previously performed. Although CCL6 is a known 
macrophage attractant (147), it will be important to demonstrate if CCL6 is 
sufficient to recruit macrophages in the environment of the upper respiratory 
tract. To address this, we could intranasally administer exogenous CCL6 to 
colonized Il1r1-/- mice and monitor the presence of immune cell infiltrates, 
specifically the population of monocytes/macrophages, in lavages of the 
nasopharynx. We could also monitor whether administration of recombinant 
cytokine has an effect on bacterial clearance.  
 Determining which cells in the respiratory tract are the source of CCL6 
is another question that remains to be addressed. CCL6 is produced by 
cultured macrophages (147, 207), as well as epithelial cells of the gut (145), 
making both of these cell types potential candidates. Furthermore, mRNA 
present in RLT lysis lavages of the upper respiratory tract is predominantly 
derived from epithelial cells of the mucosal barrier, suggesting that they are 
likely to be a source of CCL6. To test this hypothesis, we could section the 
upper respiratory tracts of mock infected or colonized mice and conduct 
immunofluorescence staining and imagining for the presence of CCL6. As 
CCL6 is a secreted protein, it may still be difficult to detect this chemokine 
within any cell population in vivo, in which case, in vitro cell culture could be 
informative.  
To address the potential contribution of macrophages to the production 
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of CCL6, we could infect bone marrow-derived macrophages with S. 
pneumoniae and monitor for the transcription and production of C-C motif 
chemokines, including CCL6. Similar experiments have characterized CCL2 
production by macrophages (60), and macrophages elicited in a model of 
irritant peritonitis are sources of CCL6 at later time points (147, 285).  
 CCL6 has been identified only in rodents and has two human 
homologs, CCL14 and CCL15, which share 36 and 53 percent amino acid 
identity with CCL6, respectively (145). The lack of a clear homolog in 
humans is a limitation of using a murine model. Therefore, determining 
whether either, or both, CCL14 and CCL15 are expressed as a result of S. 
pneumoniae sensing will be important for relating our findings to human 
carriage or disease. If prior experiments in murine cells show that 
macrophages produce and secrete CCL6 upon pneumococcal infection, we 
could perform similar experiments with human macrophages differentiated 
from blood monocytes and assay for both CCL14 and CCL15. Alternatively, 
we could use the monocyte derived THP1 cell line, that can phagocytose and 
kill pneumococci (225). Studies investigating chemokine production during S. 
pneumoniae infection have characterized a role for macrophage-produced IL-
1β in driving production of the neutrophil chemokine CXCL8 by epithelial cells 
(168). We could conduct co-culture experiments in vitro to address the 
possibility that macrophage infection with S. pneumoniae results in 
production of IL-1 cytokines that are sensed by the epithelium, which then 
drives CCL14 or CCL15 expression and secretion. Together, these 
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experiments will better define the relationship between S. pneumoniae 
colonization, IL-1 family cytokines, and chemokine production. 
 
Determine the contribution of cytosolic access in colonization of other 
mucosal pathogens 
Ascertaining whether our findings can be generalized to other 
extracellular pathogens is a broader area of possible future inquiry. The 
implications for carriage of Staphylococcus aureus are of specific interest, 
particularly because S. aureus is second only to S. pneumoniae as a cause of 
pyogenic infections in MYD88 and IRAK-4-deficient patients (146). Similar to 
the pneumococcus, S. aureus is a colonizer of the host mucosal surfaces and 
can exist as both a pathogen and a commensal. While S. aureus can be 
isolated from non-mucosal surfaces such as the skin and frequently causes 
wound and soft tissue infections, the anterior nasopharynx is the most 
common site of colonization in humans (279). Carriage in the nasopharynx is 
believed to be the reservoir for colonization of other body sites and the 
source of disease (69).  
There is evidence that cytosolic access of S. aureus bacterial 
components occurs during infection and is important for host defense. Nod2 
sensing is dependent on S. aureus expression of the pore-forming α-toxin 
and is critical for host control of cutaneous infection (115). Furthermore, S. 
aureus activates the NLRP3 inflammasome in macrophages in a manner that 
is dependent on lysozyme (243), though this pro-inflammatory cell death 
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may contribute to immunopathogenesis during pulmonary infection (135). 
The role of this innate immune recognition to S. aureus colonization and 
carriage is unknown. 
Colonization by S. aureus has historically been challenging to study 
due to the paucity of identified strains that can establish and persist in 
mouse models (154). Recently, studies have identified strains that colonize 
the murine anterior nasopharynx for a duration of weeks (5, 111), allowing 
an opportunity to better examine the role of host innate immune responses 
to S. aureus carriage. 
 
 
Concluding Remarks 
Accessing the cytosol is considered a conserved motif among 
pathogenic organisms (268) and host detection of cytosolic access is 
essential for discrimination between a pathogen and a commensal. 
Intriguingly, Streptococcus pneumoniae, a leading extracellular pathogen, 
activates intracellular innate immune signaling pathways, which contributes 
to host defense against colonization and disease by this organism. The 
studies presented here focused on the mechanism and consequences of 
cytosolic access by S. pneumoniae. 
While many microbes access the cytosol to promote their replication, 
cytosolic access of pneumococcal components follows a fatal event for the 
pneumococcus. Our studies show that bacterial products access the cytosol in 
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a manner that is dependent on the pore-forming toxin pneumolysin and 
suggest that lysozyme degradation in the phagosome triggers toxin release. 
Detection of the virulence activity of a pore-forming toxin, even if it is 
produced by a microbe a phagocyte has killed, may provide the host a signal 
that this organism is potentially pathogenic and should be cleared although it 
is not causing disease. 
 We further demonstrate that cytosolic access results in phagocyte 
death and release of cytokines that promote inflammation, immune cell 
recruitment, and bacterial clearance, but do not contribute to the 
development of adaptive immunity. Inflammatory responses in the 
nasopharynx may promote pneumococcal growth and transmission and our 
findings provide important new insights into the dynamics of the 
pneumococcus’ lifestyle and the potential contribution of its pore-forming 
toxin pneumolysin.  
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Figure 4.1. Model of cytosolic access of pneumococcal components. 
(A) S. pneumoniae is phagocytosed and subsequently degraded by lysozyme. 
This releases the pore-forming toxin pneumolysin (Ply), which facilitates 
transit of bacterial components across the phagosome membrane to the 
cytosol. There, they activate Nod2 signaling, resulting in cytokine production 
and eventually clearance of colonization. Host sensing of Ply activates p38 
MAPK signaling, which limits cytosolic access however, this phenomenon is 
fatal for the macrophage (MΦ) and results in host cell death. !
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Figure 4.2. Model of IL-1 sensing and clearance of pneumococcal 
colonization. 
(A) Cytosolic access of pneumococcal components occurs after degradation 
by lysozyme and release of pneumolysin (Ply). This event triggers 
inflammasome  (NLRP3 and AIM2) formation that leads to activation of 
caspase-1 and secretion of interleukin-1 beta (IL-β) and possibly interleukin-
1 alpha (IL-1α). Sensing of IL-1 cytokines by the IL-1 receptor (IL-1R) 
promotes clearance of S. pneumoniae colonization, potentially through 
increased levels of the macrophage attractant C-C motif chemokine 6 
(CCL6). !!
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